前往化源商城

60-82-2 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Staphylococcus aureus
External ID: CHEMBL1943200
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2012
Volume: 22
Issue: 1
First Page: 225
Last Page: 230
DOI: 10.1016/j.bmcl.2011.11.059

Target ChEMBL ID: CHEMBL352
ChEMBL Target Name: Staphylococcus aureus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=250ug.mL-1
MIC=0.8ug.mL-1
MIC=62.5ug.mL-1
MIC=125ug.mL-1
MIC>=1000ug.mL-1
MIC>=1000ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Staphylococcus aureus
External ID: CHEMBL1943199
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2012
Volume: 22
Issue: 1
First Page: 225
Last Page: 230
DOI: 10.1016/j.bmcl.2011.11.059

Target ChEMBL ID: CHEMBL352
ChEMBL Target Name: Staphylococcus aureus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=250ug.mL-1
MIC=0.8ug.mL-1
MIC=62.5ug.mL-1
MIC=62.5ug.mL-1
MIC>=1000ug.mL-1
MIC>=1000ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Staphylococcus aureus
External ID: CHEMBL1943202
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2012
Volume: 22
Issue: 1
First Page: 225
Last Page: 230
DOI: 10.1016/j.bmcl.2011.11.059

Target ChEMBL ID: CHEMBL352
ChEMBL Target Name: Staphylococcus aureus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=250ug.mL-1
MIC=0.8ug.mL-1
MIC=62.5ug.mL-1
MIC=62.5ug.mL-1
MIC>=1000ug.mL-1
MIC>=1000ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1266185
Protocol: N/A
Comment: Journal: Nat Chem Biol
Year: 2007
Volume: 3
Issue: 5
First Page: 268
Last Page: 273
DOI: 10.1038/nchembio873
Standard TypeStandard UnitsActivity Comment
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: SNCA-p-activity-luciferase
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION

1; Cells; 4 uL; Dispense 1500 HEK-293-SNCA-luc cells/well into Greiner 1536-well white / solid bottom tissue culture treated plate. The plate was covered with metal lids with gas-exchange holes.
2; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
3; Compounds; 23 nL; Compounds and controls were transferred via a Kalypsys Pin Tool (Wako USA) equipped with a 1536-slotted pin array. The plate was covered with metal lids with gas-exchange holes.
4; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
5; Dispense; 1 uL; Dispense Gly-Phe-7-amino-4-trifluoromethylcoumarin (GF-AFC, prepared at 125 uM in PBS) was added. The plate was covered with metal lids with gas-exchange holes.
6; Incubate; 30 min; Incubate at 37C, 5% CO2.
7; Detector; Fluorescence; Measure fluorescence with ViewLux microplate reader (PerkinElmer) equipped with 405/10 excitation and 540/25 emission filters.
8; Dispense; 3 uL; Dispense ONE-Glo (PerkinElmer) lucifase detection reagent was added to each well. Plates were covered with metal lids with gas-exchange holes.
9; Incubate; 15 min; Incubate at room temperature.
10; Detector; Luminescence; Measure luminescence with ViewLux microplate reader (PerkinElmer) equipped with clear filters.

NOTES (numbers refer to sequence above)
1; HEK-293-SNCA-luc were cultured and suspended in phenol-red free DMEM (4.5 g/L glucose, 25 mM HEPES, cat #21063 (Thermo)).
3; Compounds were added to the assay plate in an 11-point intra plate dose response, 1:3 titration in DMSO with a final concentration range of xxx - yyy uM. Vehicle-only plates, with DMSO being pin-transferred to every well, were inserted at the beginning of screening runs to confirm expected assay performance. Activity was normalized to wells containing medium only (-100% activity, full inhibition) and SNCA-luc cells treated with DMSO vehicle control (0% activity), contained on the same plate as test samples.
10; Signals were analyzed, and dose-response curves were fit using the Hill equation. Compounds in curve classes -1.1, -1.2, -2.1, -2.2 in the SNCA-luc assay were considered active. Compounds were eliminated from further consideration if also active (curve class -1.1, -1.2, -1.3, -1.4, -2.1, -2.2, -2.3, -2.4) in the GF-AFC cytotoxicity assay.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000386857 uMActivity at 0.0001060182 uMActivity at 0.0001896372 uMActivity at 0.0004510146 uMActivity at 0.0007501981 uMActivity at 0.0009728036 uMActivity at 0.00288 uMActivity at 0.00508 uMActivity at 0.00871 uMActivity at 0.015 uMActivity at 0.026 uMActivity at 0.053 uMActivity at 0.079 uMActivity at 0.232 uMActivity at 0.457 uMActivity at 0.692 uMActivity at 1.068 uMActivity at 2.292 uMActivity at 3.859 uMActivity at 11.39 uMActivity at 17.02 uMActivity at 25.62 uMActivity at 57.25 uMActivity at 87.55 uMActivity at 183.4 uMActivity at 286.0 uMCompound QC
Inactive0-6.754.95490.97270.090117.540 0 0 18.940815.9527-1.59161.49698.9408QC'd by Sytravon
Inactive0-5.34.0950.99965.5-7.782340 0 0 1-11.1081-7.5736-7.73535.034-11.1081QC'd by Sytravon
Inactive0-5.154.95490.907-15.92079.540 0 0 117.87255.287413.9021-13.683917.8725QC'd by Sytravon
Activator35.481346.40950Single point of activity-4.452.5884145.9404-0.469131 0 0 035.59340.1678-0.39091.93335.593QC'd by Sytravon
Activator39.810772.26460Single point of activity-4.44.95490.951568.1912-4.073330 0 0 058.01175.8738-9.2278-8.522458.0117QC'd by Sytravon
Activator14.125445.33190Partial curve; partial efficacy; poor fit-4.852.40640.998240.7728-4.55912.41 0 0 040.0933-24.9557-3.884511.525440.0933QC'd by Sytravon
Inactive0-5.754.95490.9291-20.608633.154541 0 0 0-12.846445.456928.2161-28.42-12.8464QC'd by Sytravon
Inactive0-4.354.95490.855-24.2184-0.540 0 0 0-18.932-3.6477-2.4094.988-18.932QC'd by Sytravon
Inactive0-4.73.62720.862515-8.552340 0 0 014.477-2.951-13.7936-5.964614.477QC'd by Sytravon
Inactive0-6.74.95490.66373-16.86440 0 0 08.8169-15.726.3794-6.35998.8169QC'd by Sytravon
Inactive0-4.752.40640.999921.5-2.410141 0 0 020.218433.3778-2.42513.577120.2184QC'd by Sytravon
Inactive0-4.44.95490.81172.5-8.34540 0 0 01.096-8.966-5.5054-11.12091.096QC'd by Sytravon
Activator39.810738.79450Single point of activity-4.44.95490.624141.75572.961230 0 0 036.203921.355-6.3904-4.532536.2039QC'd by Sytravon
Inactive0-6.054.0950.9994-6.05182040 0 0 120.515619.73771.4122-6.293220.5156QC'd by Sytravon
Inactive0-5.24.095110.5-10.168341 0 0 1-15.988436.1362-10.14028.7939-15.9884QC'd by Sytravon
Inactive0-6.51.39050.9999-24.2410.274540 0 0 1-5.5981-4.3546-20.7587-23.9509-5.5981QC'd by Sytravon
Inactive0-6.84.95490.711-2.44592140 0 0 0-3.345317.3219-9.95495.5495-3.3453QC'd by Sytravon
Activator39.810747.8090Partial curve; partial efficacy; poor fit-4.44.95490.521250.23992.43092.40 0 0 043.472230.2363-10.9855-11.514343.4722QC'd by Sytravon
Activator22.387275.50810Partial curve; high efficacy; poor fit-4.651.96730.982996.532421.02432.30 0 0 086.498526.093216.336536.261386.4985QC'd by Sytravon
Inactive0-6.84.95490.7429-1-13.073840 0 0 01.8063-11.31150.8702-5.17571.8063QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Staphylococcus aureus
External ID: CHEMBL1943201
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2012
Volume: 22
Issue: 1
First Page: 225
Last Page: 230
DOI: 10.1016/j.bmcl.2011.11.059

Target ChEMBL ID: CHEMBL352
ChEMBL Target Name: Staphylococcus aureus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=250ug.mL-1
MIC=0.8ug.mL-1
MIC=62.5ug.mL-1
MIC=62.5ug.mL-1
MIC>=1000ug.mL-1
MIC>=1000ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Staphylococcus aureus
External ID: CHEMBL1943204
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2012
Volume: 22
Issue: 1
First Page: 225
Last Page: 230
DOI: 10.1016/j.bmcl.2011.11.059

Target ChEMBL ID: CHEMBL352
ChEMBL Target Name: Staphylococcus aureus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=250ug.mL-1
MIC=0.8ug.mL-1
MIC=62.5ug.mL-1
MIC=62.5ug.mL-1
MIC>=1000ug.mL-1
MIC>=1000ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Staphylococcus aureus
External ID: CHEMBL1943203
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2012
Volume: 22
Issue: 1
First Page: 225
Last Page: 230
DOI: 10.1016/j.bmcl.2011.11.059

Target ChEMBL ID: CHEMBL352
ChEMBL Target Name: Staphylococcus aureus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=250ug.mL-1
MIC=0.8ug.mL-1
MIC=62.5ug.mL-1
MIC=125ug.mL-1
MIC>=1000ug.mL-1
MIC>=1000ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:muscarinic acetylcholine receptor M1 [Homo sapiens]
External ID: CHRM1_AG_FLUO8_1536_1X%ACT PRUN
Protocol: Assay Overview:

The purpose of this assay is to identify compounds that act as agonists of the human M1 muscarinic receptor (CHRM1; M1). In this assay, CHO-K1 cells stably expressing human M1 are loaded, intracellularly with the calcium indicator dye, Fluo-8, followed by treatment with agonist control or test compounds. As designed, compounds that act as CHRM1 agonists will increase intracellular calcium mobilization, resulting in increased relative fluorescence of the indicator dye and well fluorescence. Compounds are tested in singlicate at a final nominal concentration of 3 uM.

Protocol Summary:

The CHO-hM1 cell line was routinely cultured in T-175 sq cm flasks at 37 C and 95% relative humidity (RH). The growth media consisted of Ham's F-12 Nutrient Media (F-12) supplemented with 10% v/v heat-inactivated qualified fetal bovine serum, 20 mM HEPES, 50 ug/mL Geneticin, and 1X antibiotic mix (penicillin and streptomycin).

The day before the assay 3000 cells in 3 uL of growth media were seeded into each well of 1536 well microtiter plates and allowed to incubate at 37 C, 5% CO2, and 95 % RH for 17-24 hours. Next, 2 uL of the fluorogenic Fluo-8 intracellular calcium indicator mixture (prepared according to the manufacturer's protocol) was added to each well. Plates were then incubated for 1 hour at 37 C, 5% CO2, and 95 % RH, followed by 30 minute incubation at room temperature. Then, 15 nL of test compound in DMSO were dispensed to appropriate wells. The assay was started by performing a basal read of plate fluorescence (470-495 nm excitation and 515-575 nm emission) for 5 seconds on the FLIPR Tetra (Molecular Devices). Then a real time fluorescence measurement was immediately performed for the remaining 140 seconds of the assay. A ratio for each well was calculated to normalize assay data, according to the following mathematical expression:

Ratio = I_Max / I_Min

Where:

I_Max represents the maximum measured fluorescence emission intensity over the 140 second read.
I_Min represents the minimum (basal) measured fluorescence emission intensity before compound was added.

The percent activation was calculated from the median ratio as follows:

%_Activation = ( ( Ratio_Test_Compound - Median_Ratio_Low_Control ) / ( Median_Ratio_High_Control - Median_Ratio_Low_Control ) ) * 100

Where:

Test_Compound is defined as wells containing test compound.
Low_Control is defined as wells containing DMSO.
High_Control is defined as wells containing Acetylcholine (EC100) and DMSO.

PubChem Activity Outcome and Score:

A mathematical algorithm was used to determine nominally activating compounds in the primary screen. Two values were calculated for each assay plate: (1) the average percent activation of test compound wells and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter for the entire run, i.e. any compound that exhibited greater % activation than the entire screen's cutoff parameter was declared active.

The reported PubChem Activity Score has been normalized to 100% observed primary activation. Negative % activation values are reported as activity score zero.

The PubChem Activity Score range for active compounds is 100-1, and for inactive compounds 1-0.

List of Reagents:

Cell line: Chinese Hamster Ovary (CHO) cells containing hM1 receptor; (Conn Lab)
Calcium sensitive dye: Fluo-8 No Wash Calcium Assay Kit; (AAT Bioquest, part 36316)
Growth media: Ham's F-12; 10% FBS, 20mM HEPES, 50 ug/mL G418
Assay media: Ham's F-12, 10% FBS, 20 mM HEPES
Assay plates: Aurora black/clear 1536well FLIPR plate; (Aurora, part 00019326)
Probenecid: 250 mM (pH 8.0); (Sigma P8761)
Agonist: Acetylcholine (50 mM stock in water); Sigma A9187
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, and compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Activation at 3 uM
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CYP273
Protocol: Tox21 Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a BioRaptr Flying Reagent Dispenser (FRD, Beckman Coulter, Brea, CA). Compounds dissolved in DMSO and positive control (furafyllline) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000075213 uM-Replicate_1Activity at 0.0000171744 uM-Replicate_1Activity at 0.0000689059 uM-Replicate_1Activity at 0.0001619730 uM-Replicate_1Activity at 0.0003751800 uM-Replicate_1Activity at 0.0007781017 uM-Replicate_1Activity at 0.00212 uM-Replicate_1Activity at 0.00657 uM-Replicate_1Activity at 0.017 uM-Replicate_1Activity at 0.038 uM-Replicate_1Activity at 0.085 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.435 uM-Replicate_1Activity at 1.330 uM-Replicate_1Activity at 4.074 uM-Replicate_1Activity at 10.46 uM-Replicate_1Activity at 23.64 uM-Replicate_1Activity at 52.95 uM-Replicate_1Activity at 115.2 uM-Replicate_1Activity at 299.6 uM-Replicate_1Activity at 1087.9 uM-Replicate_1Activity at 2306.0 uM-Replicate_1Activity at 5157.0 uM-Replicate_1Activity at 11530.0 uM-Replicate_1Activity at 25780.0 uM-Replicate_1Activity at 57660.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-3.5643-2.3504-2.9312-2.3657-2.8224-2.60180.03942.8539-0.9099-0.8614-3.0049-2.5808-0.7-3.5643QC'd by SIGMAInactive0
Inactive0004-4.9449-1.1401-4.88281.72781.7167-2.1117-5.69640.39330.89390.1314-2.73353.195-4.9521-4.9449QC'd by SIGMAInactive0
Inactive00042.7107-2.18841.39851.45820.7693-2.47871.522.89860.9702-0.02532.12932.77661.5392.7107QC'd by EnamineInactive0
Inactive0004-2.1522-2.3143-3.894-2.36983.0635-2.9724-0.6981.807-0.3874-2.23870.0851-4.19653.0171-2.1522QC'd by SIGMAInactive0
Inactive0-4.34892.25260.8543-15.2749-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.3957-1.8486-1.8251-1.3415-0.2999-5.8043-1.46250.1520.0394-2.6869-2.4228-2.2664-9.6519-14.3957QC'd by SIGMAInactive0-4.09892.18760.881
Inactive0-4.39891.34430.8661-18.2112-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.0093-2.34660.81450.3878-0.5249-2.2045-0.0596-0.3675-2.1137-2.5302-0.6582-8.8446-8.7305-16.0093QC'd by AcrosInactive0-4.19891.62660.9372
Inactive0-4.37131.3310.7782-33.4439-3.50340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.5366-4.0189-0.7745-2.4487-0.7353-13.4714-1.9963-2.0808-1.5803-2.9931-5.0804-13.0346-7.2628-16.8143-29.5366QC'd by LightBiologicalsInactive0-4.37131.22210.9463
Inactive0-4.14891.62660.9461-28.1716-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-20.143-1.7608-0.23880.22480.5264-2.4986-0.1313-2.2365-0.2423-3.4362-3.0971-3.2181-11.2156-20.143QC'd by EnamineInhibitor79.640731.491610Partial curve; partial efficacy; poor fit-4.09892.58840.988
Inhibitor79.640737.878410Partial curve; partial efficacy; poor fit-4.09892.33320.6037-41.3784-3.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.14860.0477-0.2424-0.1109-17.1482-2.60430.09871.3021-8.8121-0.6811-2.6079-6.0005-11.8578-31.1486QC'd by LightBiologicalsInhibitor70.979933.811310Partial curve; partial efficacy; poor fit-4.14891.47870.9532
Inactive0-4.14891.3310.6595-35.6335-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-26.36121.8269-1.26512.0528-1.3342-1.1508-1.3078-0.329-8.12350.9213-0.3901-8.3475-13.4823-26.3612QC'd by LightBiologicalsInhibitor63.260940.716221Partial curve; partial efficacy-4.19891.55790.9889
Inhibitor31.7055100.219240Partial curve; high efficacy-4.49891.41630.9793-102.2947-2.0755-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-88.79751.59931.9578-0.4182-5.9156-12.3257-6.81250.6301-0.9357-7.8675-21.9718-39.1747-68.2733-88.7975QC'd by SIGMAInhibitor28.2576108.402740Partial curve; high efficacy-4.54891.24750.9984
Inactive0-4.44891.53860.9285-23.7863140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.48852.58192.144-0.92281.57780.3813-0.7273-0.01780.48032.4385-0.728-9.9293-11.8247-21.4885QC'd by SIGMAInactive0-4.39891.62590.9598
Inhibitor9.333739.896721Complete curve; partial efficacy-5.02992.04370.9899-39.89670-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-36.3129-0.2423-0.4463-0.29990.64780.36361.006-0.49871.2825-1.1546-7.8589-17.895-35.8398-36.3129QC'd by LightBiologicalsInhibitor11.750456.388421Partial curve; partial efficacy-4.92991.1110.9845
Inhibitor31.7055101.457340Partial curve; high efficacy-4.49891.1110.9982-102.7597-1.3024-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-82.349-1.7206-3.1014-1.0307-0.462-0.0614-0.5481-3.1286-4.6801-13.1432-23.5612-42.1146-67.192-82.349QC'd by SIGMAInhibitor25.184689.509140Partial curve; high efficacy-4.59891.37230.9943
Inactive0-4.39891.37230.9408-30.7143-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-27.2619-3.9038-4.25970.95220.2767-0.086-3.7725-0.0863-0.3476-4.4856-5.6587-11.4378-17.5999-27.2619QC'd by EnamineInactive0-4.39891.37230.9104
Inhibitor0.0291.537495Complete curve; high efficacy-7.69891.210.9985-95.5053-3.9679-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.9758-10.1145-26.2532-42.3865-67.4835-79.9456-90.8539-91.593-94.2489-95.4721-96.0956-96.1267-97.0582-96.9758QC'd by SIGMAInhibitor0.141694.840291Complete curve; high efficacy-6.84891.210.9987
Inhibitor70.979957.401421Partial curve; partial efficacy-4.14891.46410.9678-60.4859-3.0846-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-45.8227-1.5241-1.1304-2.119-3.4583-2.7138-4.9163-1.3699-5.0741-7.7268-8.2608-10.3758-24.1789-45.8227QC'd by TCIInhibitor63.260959.370621Partial curve; partial efficacy-4.19891.82650.9826
Inhibitor31.705588.458340Partial curve; high efficacy-4.49891.24750.9907-90.0614-1.6031-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-73.0646-2.1792-0.7242-0.9217-2.0267-1.1711-1.4022-1.5555-4.0648-12.1704-19.1709-32.2561-64.0802-73.0646QC'd by SIGMAInhibitor31.705586.838540Partial curve; high efficacy-4.49891.1110.9934
Inhibitor7.09899.944883Complete curve; high efficacy-5.14891.34430.9949-102.6257-2.681-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-98.8687-2.2636-1.9377-0.2674-0.3864-3.2139-8.5636-4.0834-14.5383-36.543-60.2337-91.3595-96.848-98.8687QC'd by TCIInhibitor5.638199.072784Complete curve; high efficacy-5.24891.62660.998
Inhibitor14.162399.52242Partial curve; high efficacy-4.84890.70.9894-100.6417-1.1197-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-88.2822-1.4919-2.9847-0.2649-1.6478-3.8502-2.8959-7.6423-18.6375-36.1235-44.1844-53.91-71.7844-88.2822QC'd by SIGMAInhibitor17.829395.774281Complete curve; high efficacy-4.74891.210.9995
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Staphylococcus aureus
External ID: CHEMBL1943206
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2012
Volume: 22
Issue: 1
First Page: 225
Last Page: 230
DOI: 10.1016/j.bmcl.2011.11.059

Target ChEMBL ID: CHEMBL352
ChEMBL Target Name: Staphylococcus aureus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=250ug.mL-1
MIC=0.8ug.mL-1
MIC=62.5ug.mL-1
MIC=125ug.mL-1
MIC>=1000ug.mL-1
MIC>=1000ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Staphylococcus aureus
External ID: CHEMBL1943205
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2012
Volume: 22
Issue: 1
First Page: 225
Last Page: 230
DOI: 10.1016/j.bmcl.2011.11.059

Target ChEMBL ID: CHEMBL352
ChEMBL Target Name: Staphylococcus aureus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=250ug.mL-1
MIC=0.8ug.mL-1
MIC=62.5ug.mL-1
MIC=125ug.mL-1
MIC>=1000ug.mL-1
MIC>=1000ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Solute carrier family 28 member 3
External ID: CHEMBL957102
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Bioorg. Med. Chem. Lett.
Year: 2009
Volume: 19
Issue: 3
First Page: 917
Last Page: 921
DOI: 10.1016/j.bmcl.2008.11.112

Target ChEMBL ID: CHEMBL5707
ChEMBL Target Name: Solute carrier family 28 member 3
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
100Ki>100000nM
100Ki>100000nM
100Ki>100000nM
100Ki>100000nM
100Ki>100000nM
53.86Ki=53860nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-keats_OPM1-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.011890.089787Complete curve; high efficacy-7.92922.47290.96942.5966132.6862-1.10 0 0 0 0 0 0 0 0 0 057.466123.2938140.8388112.24160.901644.089639.767736.478540.20639.176941.461857.466QC'd by ChemAxon
Cytotoxic0.417675.850987Complete curve; high efficacy-6.37921.53860.949872.4265148.2774-1.10 0 0 0 0 0 0 0 0 0 061.5626139.2774158.5971143.0204144.9664147.8567136.015191.815692.950575.674674.676861.5626QC'd by JohnsHopkins
Cytotoxic0.148294.419287Complete curve; high efficacy-6.82921.10.951759.4372153.8564-1.10 0 0 0 0 0 0 0 0 0 055.0456164.8354134.704151.2303143.6834134.761595.648470.062167.305676.105555.692455.0456QC'd by Selleck
Cytotoxic0.166394.102386Complete curve; high efficacy-6.77922.72020.972950.0751144.1775-1.10 0 0 0 0 0 0 0 0 0 056.0568132.0924142.9387160.1371137.1338142.289985.893148.200245.041752.603354.183256.0568QC'd by ACC
Cytotoxic0.0332121.075286Complete curve; high efficacy-7.479210.984142.1192163.1944-1.10 0 0 0 0 0 0 0 0 0 035.7472158.2854158.4708139.505123.340671.574165.258955.071850.086742.178237.195535.7472QC'd by Selleck
Cytotoxic0.742778.671685Complete curve; high efficacy-6.12921.88510.983463.6148142.2865-1.10 0 0 0 0 0 0 0 0 0 058.2475142.1116146.4992135.5304145.8795136.7066141.0466113.833174.38665.128871.886858.2475QC'd by Tocris
Cytotoxic0.833386.219185Complete curve; high efficacy-6.079210.930267.549153.7681-1.10 0 0 0 0 0 0 0 0 0 069.8532158.4753142.7847153.7541141.7507166.925141.693105.2958104.667477.221776.165269.8532QC'd by Tocris
Cytotoxic3.722164.493585Complete curve; high efficacy-5.42924.95490.792112.0642176.5577-1.10 0 0 0 0 0 0 0 0 0 089.6942158.9633166.2699180.3984167.1951174.9654191.2964181.3214193.1909122.0222135.538889.6942QC'd by Tocris
Cytotoxic0.0526123.236885Complete curve; high efficacy-7.27920.60.972433.4065156.6433-1.10 0 0 0 0 0 0 0 0 0 035.7651153.6951126.1364142.4363103.249192.595173.147860.614343.388740.031337.882135.7651QC'd by Tocris
Cytotoxic0.006677.526284Complete curve; high efficacy-8.17920.80.975321.696999.2231-1.10 0 0 0 0 0 0 0 0 0 013.262791.55276.413756.561242.193434.028331.180927.350626.077820.634320.214413.2627QC'd by Tocris
Cytotoxic0.5258123.459984Complete curve; high efficacy-6.27921.39870.968242.1223165.5821-1.10 0 0 0 0 0 0 0 0 0 025.7016164.86160.7689152.0063170.1205168.2257149.303488.213874.069651.798249.790125.7016QC'd by JohnsHopkins
Cytotoxic1.865582.375984Complete curve; high efficacy-5.72922.33320.929161.702144.078-1.10 0 0 0 0 0 0 0 0 0 051.7606136.01140.2451152.6106148.0124143.6336147.0904134.4052111.284254.479484.371251.7606QC'd by Selleck
Cytotoxic2.3485101.924784Complete curve; high efficacy-5.62920.60.955871.9549173.8795-1.10 0 0 0 0 0 0 0 0 0 091.649176.6761171.0851177.7813159.9071159.3009150.4576153.7054126.8633116.427184.815491.649QC'd by SynKinase
Cytotoxic0.018790.923784Complete curve; high efficacy-7.72920.70.995926.7347117.6584-1.10 0 0 0 0 0 0 0 0 0 029.5723109.5774101.759683.749673.379952.652141.5735.435430.241226.675925.387729.5723QC'd by Microsource
Cytotoxic0.0132127.373583Complete curve; high efficacy-7.87920.70.972217.3385144.712-1.10 0 0 0 0 0 0 0 0 0 033.7384132.8301113.247589.341775.717555.400227.741422.107814.440214.011616.778533.7384QC'd by Tocris
Cytotoxic3.722186.014283Complete curve; high efficacy-5.42921.210.972165.5416151.5558-1.10 0 0 0 0 0 0 0 0 0 066.7748154.8648146.5307153.6238147.9405153.7843144.2907154.4262119.8728100.256583.011166.7748QC'd by Tocris
Cytotoxic0.3722105.789883Complete curve; high efficacy-6.42922.84730.98436.148141.9378-1.10 0 0 0 0 0 0 0 0 0 022.8052141.9378142.9518145.1156141.0583137.6217130.508557.913351.266941.388233.000722.8052QC'd by JohnsHopkins
Cytotoxic1.6626102.314483Complete curve; high efficacy-5.779210.924240.9668143.2813-1.10 0 0 0 0 0 0 0 0 0 047.0105152.3961124.7264140.9824142.6059141.9566147.0368112.397281.287385.089138.460247.0105QC'd by Microsource
Cytotoxic0.0118140.01383Complete curve; high efficacy-7.92922.58840.998217.9926158.0057-1.10 0 0 0 0 0 0 0 0 0 014.8749156.5885154.4434130.9445.126815.310417.374218.814419.415621.188621.270814.8749QC'd by Selleck
Cytotoxic0.4686118.608983Complete curve; high efficacy-6.32921.85790.987228.1061146.7151-1.10 0 0 0 0 0 0 0 0 0 027.0205138.0525155.3457144.6536140.3247148.8544132.291370.355346.41333.133522.075327.0205QC'd by Tocris
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-OC1MY5-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.016675.705499Complete curve; high efficacy-7.77921.62590.8287113.3664189.0718-1.10 0 0 0 0 0 0 0 0 0 076.415189.0718184.1323176.4162143.7765121.3848112.8196136.1769124.1622121.4205110.84976.415QC'd by SigmaAldrich
Cytotoxic0.014878.323895Complete curve; high efficacy-7.82921.88510.884990.161168.4848-1.10 0 0 0 0 0 0 0 0 0 067.4943179.706152.1469156.7226115.95190.887181.242794.0684108.643892.5891100.356267.4943QC'd by BIOMOL
Cytotoxic0.0093193.289593Complete curve; high efficacy-8.02920.50.866672.6851265.9745-1.10 0 0 0 0 0 0 0 0 0 0105.1458244.5929174.7663172.838154.9069132.1222117.372990.589987.865585.670530.7772105.1458QC'd by Microsource
Cytotoxic0.0021162.783989Complete curve; high efficacy-8.67922.25260.909541.4972204.2812-1.10 0 0 0 0 0 0 0 0 0 016.0569187.9512112.283154.611932.400643.04248.563547.468974.45340.548125.593516.0569QC'd by Tocris
Cytotoxic0.0037168.183989Complete curve; high efficacy-8.42921.98870.95444.8326213.0165-1.10 0 0 0 0 0 0 0 0 0 016.7704206.3802163.409786.454636.022349.839739.359743.293852.688461.372857.854816.7704QC'd by Waterstone
Cytotoxic0.0469148.810689Complete curve; high efficacy-7.32922.40640.8561.7336210.5442-1.10 0 0 0 0 0 0 0 0 0 08.2046222.3206202.2319203.978192.1974118.262335.92446.047760.9187116.720798.87498.2046QC'd by ChemAxon
Cytotoxic0.0026113.270989Complete curve; high efficacy-8.57923.1320.897742.9988156.2697-1.10 0 0 0 0 0 0 0 0 0 021.2361152.3367113.413840.593638.127740.362443.602334.137943.871364.736864.064821.2361QC'd by Tocris
Cytotoxic0.0017114.495389Complete curve; high efficacy-8.77924.0950.841643.8532158.3484-1.10 0 0 0 0 0 0 0 0 0 014.1898152.803967.85254.519352.359357.345849.82462.059347.505430.836728.465514.1898QC'd by Selleck
Cytotoxic0.002672.734289Complete curve; high efficacy-8.57922.72020.907441.83114.5643-1.10 0 0 0 0 0 0 0 0 0 049.3766112.187583.595146.53530.954733.435532.312943.245244.089344.797856.003549.3766QC'd by Microsource
Cytotoxic0.0743128.224189Complete curve; high efficacy-7.12920.30.807365.0905193.3146-1.10 0 0 0 0 0 0 0 0 0 071.5247186.4209158.6743129.1227120.8146138.5824133.4969104.1228120.2992101.960377.775671.5247QC'd by Tocris
Cytotoxic0.0662125.720489Complete curve; high efficacy-7.17921.82650.971967.5385193.259-1.10 0 0 0 0 0 0 0 0 0 052.5197186.6163181.5655200.1337192.1342128.241283.363287.409864.631570.685465.116152.5197QC'd by SantaCruz Bio
Cytotoxic0.661978.285988Complete curve; high efficacy-6.17921.88510.946996.3016174.5875-1.10 0 0 0 0 0 0 0 0 0 0101.3711171.7651176.8613184.4702181.7039154.2237171.0284143.1726100.579190.9185104.0348101.3711QC'd by BIOMOL
Cytotoxic0.0935125.731288Complete curve; high efficacy-7.02923.990.970262.9518188.683-1.10 0 0 0 0 0 0 0 0 0 071.3789173.2237176.4213202.4283200.5745169.056972.067947.835455.511865.182873.840471.3789QC'd by Selleck
Cytotoxic0.0743119.127488Complete curve; high efficacy-7.12920.70.98858.8412177.9686-1.10 0 0 0 0 0 0 0 0 0 065.4007172.7284171.0856155.1599146.3776116.585999.779291.984365.419864.002856.279365.4007QC'd by Axon Medchem
Cytotoxic0.3317103.910288Complete curve; high efficacy-6.47920.30.843677.4858181.396-1.10 0 0 0 0 0 0 0 0 0 0101.3477161.302177.473153.8803133.2684139.1275144.3925135.8497117.608691.5334104.8313101.3477QC'd by Tocris
Cytotoxic0.1321123.71788Complete curve; high efficacy-6.879210.962367.9127191.6297-1.10 0 0 0 0 0 0 0 0 0 045.8939178.5371199.9241184.0193181.5655149.5884112.02994.762981.731373.616983.205245.8939QC'd by Microsource
Cytotoxic0.0066144.59188Complete curve; high efficacy-8.17922.72020.931843.5813188.1723-1.10 0 0 0 0 0 0 0 0 0 07.9675169.8483200.8523105.256949.605442.518545.303152.145650.632956.794649.51437.9675QC'd by SIGMA
Cytotoxic0.935111.476387Complete curve; high efficacy-6.02921.46410.907288.9886200.4649-1.10 0 0 0 0 0 0 0 0 0 065.9282174.089200.6763211.7975212.4609203.6327185.8171171.8065108.7421105.1811115.181865.9282QC'd by Selleck
Cytotoxic0.0118148.747387Complete curve; high efficacy-7.92921.88510.914741.9403190.6876-1.10 0 0 0 0 0 0 0 0 0 08.0822198.2962171.9006154.032174.692245.681859.094162.628163.424350.903813.29568.0822QC'd by Selleck
Cytotoxic1.662684.625787Complete curve; high efficacy-5.77922.72020.9593106.2986190.9242-1.10 1 0 0 0 0 0 0 0 0 0104.8088197.9176147.6744188.5439182.4788196.4457175.6724199.742148.305107.0547110.4851104.8088QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-KMS_34-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.041888.877985Complete curve; high efficacy-7.37921.210.83931.4966120.3746-1.10 0 0 0 0 0 0 0 0 0 07.7124132.8926100.448796.9022107.952767.422923.232138.254730.074155.763343.34537.7124QC'd by ChemAxon
Cytotoxic0.0148116.450385Complete curve; high efficacy-7.82920.40.883227.623144.0733-1.10 0 0 0 0 0 0 0 0 0 023.9089133.149384.985690.676488.203880.547548.934346.794939.846148.370238.326523.9089QC'd by Tocris
Cytotoxic0.00363.507484Complete curve; high efficacy-8.52921.24750.846222.061585.5689-1.10 0 0 0 0 0 0 0 0 0 04.685578.444856.901238.37827.125924.86230.850833.175427.356122.258211.85044.6855QC'd by AG Scientific
Cytotoxic0.066281.534784Complete curve; high efficacy-7.17920.50.935226.2812107.8158-1.10 0 0 0 0 0 0 0 0 0 041.7013104.6491.691185.710374.992566.250263.828947.143640.11632.645316.398141.7013QC'd by Microsource
Cytotoxic0.005388.857983Complete curve; high efficacy-8.27920.70.918715.3166104.1745-1.10 0 0 0 0 0 0 0 0 0 017.273995.7755.043766.176737.487330.62723.923816.028919.552917.45899.815517.2739QC'd by Toronto Research
Cytotoxic0.209387.781383Complete curve; high efficacy-6.67923.06540.98628.7833116.5646-1.10 0 0 0 0 0 0 0 0 0 028.0348105.4018124.2663111.216120.9286117.829382.793730.938430.822427.522130.01228.0348QC'd by ACC
Cytotoxic0.016684.33283Complete curve; high efficacy-7.77922.72020.984217.1644101.4964-1.10 0 0 0 0 0 0 0 0 0 016.809492.1572111.714893.822544.879723.29116.702114.931216.05218.314117.449816.8094QC'd by ChemAxon
Cytotoxic0.037278.620483Complete curve; high efficacy-7.42922.58840.984618.797997.4182-1.10 0 0 0 0 0 0 0 0 0 012.888592.420695.8169102.935482.036534.503824.164219.157513.771216.322226.468312.8885QC'd by Selleck
Cytotoxic1.04996.497783Complete curve; high efficacy-5.97920.50.957536.2422132.7399-1.10 0 0 0 0 0 0 0 0 0 054.2766130.3979127.8742134.2077109.0067109.1952107.713199.92678.571159.936952.628454.2766QC'd by LINCS
Cytotoxic0.0469113.5983Complete curve; high efficacy-7.32921.92820.977620.8655134.4556-1.10 0 0 0 0 0 0 0 0 0 021.4008136.3735118.7418147.5619108.852467.204221.009224.201124.538819.698820.300321.4008QC'd by Tocris
Cytotoxic0.0059134.11483Complete curve; high efficacy-8.22920.90.958214.3732148.4872-1.10 0 0 0 0 0 0 0 0 0 07.7187135.6994.255592.291235.67427.57326.610323.447918.96313.139211.28037.7187QC'd by Selleck
Cytotoxic0.016682.99983Complete curve; high efficacy-7.77924.44950.914818.7882101.7872-1.10 0 0 0 0 0 0 0 0 0 01.306589.3692109.2888105.280939.259712.56078.63117.245227.937241.290725.02181.3065QC'd by BIOMOL
Cytotoxic0.0026124.131382Complete curve; high efficacy-8.57921.47810.986411.3246135.4559-1.10 0 0 0 0 0 0 0 0 0 014.9487124.278272.55539.097213.763318.160410.303510.566110.76498.90756.618214.9487QC'd by Tocris
Cytotoxic0.0209112.54382Complete curve; high efficacy-7.67921.96730.932614.5764127.1195-1.10 0 0 0 0 0 0 0 0 0 00.7959123.8363116.6866132.122462.186831.22417.327713.62456.960345.1415.10240.7959QC'd by NCGCChem
Cytotoxic0.104980.762282Complete curve; high efficacy-6.97923.990.931416.214996.9771-1.10 0 0 0 0 0 0 0 0 0 02.1195101.382375.2262112.248999.869687.632124.000528.457125.40816.87938.90662.1195QC'd by ChemAxon
Cytotoxic0.234892.655582Complete curve; high efficacy-6.62920.90.986616.7612109.4167-1.10 0 0 0 0 0 0 0 0 0 013.3983112.307799.4639110.160599.618592.250163.412843.116934.989225.203720.221113.3983QC'd by JohnsHopkins
Cytotoxic0.0264105.223682Complete curve; high efficacy-7.57922.78680.988110.1409115.3645-1.10 0 0 0 0 0 0 0 0 0 05.3828108.8197112.7123124.379475.066919.974411.747517.45588.74528.59417.9615.3828QC'd by Selleck
Cytotoxic0.93588.261382Complete curve; high efficacy-6.02921.78850.855620.4336108.6949-1.10 0 0 0 0 0 0 0 0 0 04.852785.5635121.1104117.096194.650799.9913137.032269.811848.833229.794829.96994.8527QC'd by Selleck
Cytotoxic0.0059119.868782Complete curve; high efficacy-8.22920.90.98910.4647130.3334-1.10 0 0 0 0 0 0 0 0 0 09.7544119.720688.055968.561935.492830.376516.190110.80912.106211.21728.0079.7544QC'd by Tocris
Cytotoxic0.4176152.652182Complete curve; high efficacy-6.37920.40.9686-18.9995133.6526-1.10 0 0 0 0 0 0 0 0 0 02.9146127.427102.6532123.629693.093583.859362.24155.771444.320918.43846.1372.9146QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-keats_L363-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.011864.8887Complete curve; high efficacy-7.92923.990.906542.9911107.8711-1.10 0 0 0 0 0 0 0 0 0 175.9379117.166298.059101.666744.543237.931551.79645.54545.89855.696524.21575.9379QC'd by ChemAxon
Cytotoxic0.001086Complete curve; high efficacy-900.8727.00327.003-1.10 0 0 0 0 0 0 0 0 0 011.714116.109651.782338.477438.14932.576327.00321.712513.65628.24944.831811.714QC'd by Tocris
Cytotoxic0.014887.3385Complete curve; high efficacy-7.82922.72020.839428.2225115.5525-1.10 0 0 0 0 0 0 0 0 0 02.7164112.6565118.5558105.208650.461432.896456.123844.203245.685613.05273.96712.7164QC'd by ChemAxon
Cytotoxic0.074381.047985Complete curve; high efficacy-7.12922.40640.987736.057117.1048-1.10 0 0 0 0 0 0 0 0 0 036.612118.1815112.941121.7674108.916987.133342.59131.000532.05139.154343.592636.612QC'd by Selleck
Cytotoxic0.013295.183485Complete curve; high efficacy-7.87922.58840.978930.3117125.4951-1.10 0 0 0 0 0 0 0 0 0 022.3434119.5176131.0238109.768849.199641.232339.094429.184232.449924.950225.888622.3434QC'd by Tocris
Cytotoxic0.037296.952684Complete curve; high efficacy-7.42923.67720.943926.3959123.3485-1.10 0 0 0 0 0 0 0 0 0 020.4921101.7407120.2132147.5217112.769437.937439.317124.381225.076727.694220.417320.4921QC'd by Selleck
Cytotoxic0.1147102.026284Complete curve; high efficacy-6.94040.40.945728.8277130.8539-1.10 0 0 0 0 0 0 0 0 0 1108.0014122.9006125.5314115.924689.870995.612875.420675.658466.669245.064945.6837108.0014QC'd by Selleck
Cytotoxic0.009390.158484Complete curve; high efficacy-8.02921.71370.962524.1405114.2989-1.10 0 0 0 0 0 0 0 0 0 020.1633106.7519116.404475.80742.460431.644837.517319.116617.345730.109618.866820.1633QC'd by NCGCChem
Cytotoxic0.468669.609184Complete curve; high efficacy-6.32921.69240.827647.7156117.3247-1.10 0 0 0 0 0 0 0 0 0 195.324899.0689105.4815112.5472134.071139.294895.863678.07556.20561.315734.97695.3248QC'd by Microsource
Cytotoxic0.295785.225883Complete curve; high efficacy-6.52924.95490.905530.0023115.2281-1.10 0 0 0 0 0 0 0 0 1 045.1208102.1961108.7224107.4279107.404145.4631114.174621.348922.64833.189677.55645.1208QC'd by NCGCChem
Cytotoxic0.0118107.387883Complete curve; high efficacy-7.92924.44950.994618.1514125.5392-1.10 0 0 0 0 0 0 0 0 0 1103.6539130.2388120.1313117.134124.788321.804212.746820.289419.91221.366715.3748103.6539QC'd by Selleck
Cytotoxic0.033278.333383Complete curve; high efficacy-7.47924.44950.957520.808999.1422-1.10 0 0 0 0 0 0 0 0 0 1105.677694.56286.401118.767388.388324.521523.716318.859423.322922.567716.9857105.6776QC'd by Chemscene
Cytotoxic0.011886.29183Complete curve; high efficacy-7.92920.910.971220.4028106.6938-1.10 0 0 0 0 0 0 0 0 0 013.990798.3598100.650970.772445.884940.959433.218425.044519.165723.31217.822613.9907QC'd by Selleck
Cytotoxic0.234884.542283Complete curve; high efficacy-6.62921.10.954725.2427109.7849-1.10 0 0 0 0 0 0 0 0 0 1114.3833102.02113.1558103.8422121.074381.328372.684251.920531.812126.372328.0582114.3833QC'd by ChemieTek
Cytotoxic0.014886.1283Complete curve; high efficacy-7.82922.18760.972516.3085102.4286-1.10 0 0 0 0 0 0 0 0 0 07.9507102.926198.733390.777842.92222.299723.200730.230611.653910.657913.08247.9507QC'd by Selleck
Cytotoxic0.148277.093883Complete curve; high efficacy-6.82924.95490.955322.412899.5066-1.10 0 0 0 0 0 0 0 0 0 09.87102.096792.544998.652790.3526113.472742.025228.643431.5424.979314.77199.87QC'd by Chemscene
Cytotoxic0.417691.373683Complete curve; high efficacy-6.37921.69240.985829.7282121.1017-1.10 0 1 0 0 0 0 0 0 0 021.3801116.2452129.3034186.5441118.5918113.5565105.088162.785435.762934.74535.353721.3801QC'd by Selleck
Cytotoxic1.04987.361683Complete curve; high efficacy-5.979210.877236.1973123.5589-1.10 0 0 0 0 0 0 0 0 0 054.1491117.4289109.6638131.7472129.0154136.577793.933688.945583.642543.457225.12354.1491QC'd by SynKinase
Cytotoxic0.1482113.990583Complete curve; high efficacy-6.82921.28760.888823.8075137.7981-1.10 0 0 0 0 0 0 0 0 0 08.0453114.2505119.5624176.2421137.6679106.682559.028455.250738.182324.837127.40678.0453QC'd by Tocris
Cytotoxic1.17785.496383Complete curve; high efficacy-5.92923.62720.914939.2135124.7097-1.10 0 0 0 0 0 0 0 0 0 027.6517113.2381135.3021111.0564135.5045142.3677111.5001118.811556.830633.204257.637227.6517QC'd by Microsource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-keats_OCIMY7-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.0148138.417292Complete curve; high efficacy-7.82920.80.985473.4473211.8645-1.10 0 0 0 0 0 0 0 0 0 076.0615206.4576176.3477160.675143.036102.215687.458676.386675.942381.513271.284576.0615QC'd by Selleck
Cytotoxic0.1865129.709492Complete curve; high efficacy-6.72922.47290.9102104.5908234.3002-1.10 0 0 0 0 0 0 0 0 0 097.9499212.7695199.584247.0735277.3731227.6905162.5507123.8591102.5004104.1059104.398997.9499QC'd by SantaCruz Bio
Cytotoxic0.525872.960991Complete curve; high efficacy-6.27922.72020.9263121.6641194.625-1.10 0 0 0 0 0 0 0 0 0 1182.846196.2276201.2704206.5478177.6678187.1047193.8819153.4274124.7553110.5225133.7805182.846QC'd by SIGMA
Cytotoxic0.0469134.726691Complete curve; high efficacy-7.32922.33320.942779.2711213.9977-1.10 0 0 0 0 0 0 0 0 0 074.524225.8348183.7696233.1661192.207130.243974.8439101.457875.21388.15864.064774.524QC'd by Selleck
Cytotoxic0.001091Complete curve; high efficacy-900.973648.780348.7803-1.10 0 0 0 0 0 0 0 0 0 047.83166.158106.533567.344835.203147.280344.656348.780346.703651.704556.888247.83QC'd by Tocris
Cytotoxic0.001090Complete curve; high efficacy-900.820746.422646.4226-1.10 0 0 0 0 0 0 0 0 0 05.4032205.1041113.398945.042360.965955.970682.491946.422618.259210.66488.46975.4032QC'd by Tocris
Cytotoxic1.481867.805689Complete curve; high efficacy-5.82924.95490.7621141.433209.2386-1.10 0 0 0 0 0 0 0 0 0 0116.0869187.3686222.298199.2101217.5801185.2508221.0682234.3031161.6854158.4572150.9575116.0869QC'd by ChemAxon
Cytotoxic0.001089Complete curve; high efficacy-900.959138.870638.8706-1.10 0 0 0 0 0 0 0 0 0 039.1109165.4745147.989392.122638.870647.652815.964314.55779.16457.80787.070839.1109QC'd by Selleck
Cytotoxic0.001089Complete curve; high efficacy-900.938841.142141.1421-1.10 0 0 0 0 0 0 0 0 0 03.8961184.0933141.73391.783118.669184.427141.142140.416126.249718.52235.72733.8961QC'd by Selleck
Cytotoxic0.001089Complete curve; high efficacy-900.988840.837940.8379-1.11 0 0 0 0 0 0 0 0 0 026.1407121.6554195.8384155.511388.106368.094737.765640.837940.099127.971631.77326.1407QC'd by Selleck
Cytotoxic0.038292.573488Complete curve; high efficacy-7.4180.40.889752.7945145.3679-1.10 0 0 0 0 0 0 0 0 0 051.9291116.2057136.3435103.092491.965479.473982.026983.101367.37361.55557.499951.9291QC'd by ChemPacific
Cytotoxic0.0743134.535488Complete curve; high efficacy-7.12921.210.930757.9113192.4467-1.10 0 0 0 0 0 0 0 0 0 049.7147175.8519207.2976185.8686162.8742143.048663.049199.107467.380557.937949.251549.7147QC'd by ChemAxon
Cytotoxic0.001088Complete curve; high efficacy-900.875833.721233.7212-1.10 0 0 0 0 0 0 0 0 0 04.1324152.461297.589368.749932.264258.815947.257833.72128.80494.81863.54334.1324QC'd by Microsource
Cytotoxic3.722185.223987Complete curve; high efficacy-5.42924.95490.891150.0271235.251-1.11 0 0 0 0 0 0 0 0 0 0154.7033204.9209231.691212.9559243.8102227.9286234.025230.2626264.0915159.589149.6383154.7033QC'd by SIGMA
Cytotoxic1.3207106.100387Complete curve; high efficacy-5.87921.82650.9417105.4088211.509-1.10 0 0 0 0 0 0 0 0 0 0114.0374223.8378192.8578196.2457228.3532212.5214209.5506192.8647146.6919120.128291.3668114.0374QC'd by XcessBio
Cytotoxic0.1482151.498787Complete curve; high efficacy-6.82920.70.9856.0265207.5252-1.10 1 0 0 0 0 0 0 0 0 051.814202.2596122.7624197.3713167.7834153.3308139.098485.59679.140368.517869.503551.814QC'd by Selleck
Cytotoxic0.093570.605687Complete curve; high efficacy-7.02924.50450.961352.9846123.5901-1.10 1 0 0 0 0 0 0 0 0 041.374115.1832175.7294133.236122.1014112.51554.255357.095263.733753.56750.781741.374QC'd by SynKinase
Cytotoxic0.001087Complete curve; high efficacy-900.957630.251130.2511-1.10 0 0 0 0 0 0 0 0 0 07.7137142.2621159.750441.789140.52422.573521.992937.056330.251115.915614.28657.7137QC'd by Selleck
Cytotoxic0.001087Complete curve; high efficacy-900.935330.652530.6525-1.10 0 0 0 0 0 0 0 0 0 010.0983153.490588.457756.636528.973143.343733.830730.652518.384511.756211.590310.0983QC'd by Selleck
Cytotoxic0.2635171.464186Complete curve; high efficacy-6.57924.95490.90355.2524226.7165-1.10 0 0 0 0 0 0 0 0 0 087.6192224.0953196.7275198.1303295.2794221.4309194.687546.556551.514833.151858.588387.6192QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Staphylococcus aureus
External ID: CHEMBL1943208
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2012
Volume: 22
Issue: 1
First Page: 225
Last Page: 230
DOI: 10.1016/j.bmcl.2011.11.059

Target ChEMBL ID: CHEMBL352
ChEMBL Target Name: Staphylococcus aureus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=250ug.mL-1
MIC=0.4ug.mL-1
MIC=62.5ug.mL-1
MIC=62.5ug.mL-1
MIC>=1000ug.mL-1
MIC>=1000ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-MM1R-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.0093104.652788Complete curve; high efficacy-8.02921.96730.994643.2871147.9397-1.10 0 0 0 0 0 0 0 0 0 046.9856151.2515136.3124112.156860.347441.289143.600645.536740.858441.487544.24846.9856QC'd by Cayman
Cytotoxic0.052690.729187Complete curve; high efficacy-7.27921.24750.96949.3002140.0293-1.10 0 0 0 0 0 0 0 0 0 036.2116136.8931136.6639140.7519111.565496.338258.16355.06458.665957.368148.852936.2116QC'd by Selleck
Cytotoxic0.1865111.099886Complete curve; high efficacy-6.72921.55790.959758.0636169.1634-1.10 0 0 0 0 0 0 0 0 0 030.8392165.6134164.7399166.9572172.8379153.7472111.421772.293771.432370.561564.820230.8392QC'd by Tocris
Cytotoxic0.104999.253786Complete curve; high efficacy-6.97923.1320.878851.4415150.6952-1.10 0 0 0 0 0 0 0 0 0 04.3763133.6762159.094152.6324154.4225134.385464.985170.629468.541858.555955.58134.3763QC'd by Selleck
Cytotoxic0.331794.992984Complete curve; high efficacy-6.47920.30.952137.641132.6338-1.10 0 0 0 0 0 0 0 0 0 050.4436114.4568123.9845113.833196.15292.162489.666481.881579.922468.155859.613750.4436QC'd by Tocris
Cytotoxic0.742784.904484Complete curve; high efficacy-6.12922.25260.93345.6644130.5688-1.10 0 0 0 0 0 0 0 0 0 036.4643134.3384115.1991125.3701119.0101144.1666143.817297.989150.782553.051854.389936.4643QC'd by Tocris
Cytotoxic0.833375.35484Complete curve; high efficacy-6.07923.990.961446.5835121.9376-1.10 0 0 0 0 0 0 0 0 0 033.0973124.2208119.0164110.2614120.2463126.3612130.9298108.885950.932550.258656.053633.0973QC'd by Selleck
Cytotoxic0.372288.076284Complete curve; high efficacy-6.42924.44950.970337.6549125.7311-1.10 0 0 0 0 0 0 0 0 0 044.0074106.5992127.2247130.6238138.3415127.8948120.698748.218435.913536.364134.92644.0074QC'd by Selleck
Cytotoxic0.0093130.642584Complete curve; high efficacy-8.02920.90.986724.621155.2635-1.10 0 0 0 0 0 0 0 0 0 018.1076143.3641125.709898.568566.033436.988237.469536.872131.027325.006419.273518.1076QC'd by Toronto Research
Cytotoxic0.468684.349983Complete curve; high efficacy-6.32923.06540.892737.763122.1129-1.10 0 0 0 0 0 0 0 0 0 08.9174100.9718133.1095113.0152128.6977133.2765119.584364.278453.378148.528644.758.9174QC'd by SynKinase
Cytotoxic0.331788.677483Complete curve; high efficacy-6.47921.62590.990934.1483122.8257-1.10 0 0 0 0 0 0 0 0 0 032.8455112.8257122.9968126.477124.3559121.535296.460460.397143.403334.092232.873332.8455QC'd by JohnsHopkins
Cytotoxic0.2957104.439583Complete curve; high efficacy-6.52920.60.963633.4657137.9052-1.10 0 0 0 0 0 0 0 0 0 030.41139.5422127.9789115.7906133.779110.19387.959673.595558.104955.361347.914130.41QC'd by JohnsHopkins
Cytotoxic2.348586.675883Complete curve; high efficacy-5.62924.0950.968453.6121140.2879-1.10 0 0 0 0 0 0 0 0 0 051.2528135.5146146.9511127.3268148.5202130.0159143.2286148.4195122.370157.612755.742751.2528QC'd by LINCS
Cytotoxic0.589978.481583Complete curve; high efficacy-6.229210.96239.6422118.1236-1.10 0 0 0 0 0 0 0 0 0 036.8849113.0988105.5924123.1519126.3882114.847893.448478.396461.99652.62141.616136.8849QC'd by NCGCChem
Cytotoxic1.662685.967283Complete curve; high efficacy-5.77922.47290.929540.7279126.6952-1.10 0 0 0 0 0 0 0 0 0 028.4756118.8121112.7597122.0662124.4452131.3159149.7541122.838280.294449.812550.994128.4756QC'd by Microsource
Cytotoxic0.074390.741383Complete curve; high efficacy-7.12921.96730.946425.6492116.3905-1.10 0 0 0 0 0 0 0 0 0 05.9198106.5785111.2723128.5693109.673979.414437.115833.672241.61829.688719.14745.9198QC'd by Selleck
Cytotoxic0.4176196.850483Complete curve; high efficacy-6.37920.30.9606-31.7676165.0828-1.10 0 0 0 0 0 0 0 0 0 02.8348135.921148.6439123.1507111.473178.544671.308564.760262.7228.685414.04622.8348QC'd by Microsource
Cytotoxic0.525895.995583Complete curve; high efficacy-6.27920.40.975335.9633131.9588-1.10 0 0 0 0 0 0 0 0 0 050.6988124.3759129.0401111.2096110.666498.319199.274582.50577.957559.853253.136550.6988QC'd by Microsource
Cytotoxic0.1865153.297482Complete curve; high efficacy-6.72920.40.9838-19.1976134.0998-1.10 0 0 0 0 0 0 0 0 0 01.5971128.3939102.50195.957690.349376.112759.654643.641425.05494.92791.71.5971QC'd by NCGCChem
Cytotoxic0.4686112.636982Complete curve; high efficacy-6.32920.70.96616.772129.4089-1.10 0 0 0 0 0 0 0 0 0 013.877117.2722122.3984135.2437130.0817105.741580.360967.039351.753440.54130.169413.877QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Staphylococcus aureus
External ID: CHEMBL1943207
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2012
Volume: 22
Issue: 1
First Page: 225
Last Page: 230
DOI: 10.1016/j.bmcl.2011.11.059

Target ChEMBL ID: CHEMBL352
ChEMBL Target Name: Staphylococcus aureus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=250ug.mL-1
MIC=0.4ug.mL-1
MIC=62.5ug.mL-1
MIC=62.5ug.mL-1
MIC>=1000ug.mL-1
MIC>=1000ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-mm1s-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.013278.888888Complete curve; high efficacy-7.87923.51170.995147.2347126.1235-1.10 0 0 0 0 0 0 0 0 0 042.2827127.6613122.708120.202461.112651.288545.516147.740746.357847.533948.054342.2827QC'd by SigmaAldrich
Cytotoxic0.018794.499187Complete curve; high efficacy-7.72921.96730.992343.1973137.6963-1.10 0 0 0 0 0 0 0 0 0 047.5181141.319129.8171127.504186.807649.094247.049942.27740.938537.815144.862147.5181QC'd by ACC
Cytotoxic0.525873.986887Complete curve; high efficacy-6.27921.53860.960875.2185149.2053-1.10 0 0 0 0 0 0 0 0 0 066.1566142.7053154.8249147.903146.0134146.4254144.006104.273988.096990.959471.649566.1566QC'd by JohnsHopkins
Cytotoxic0.0059140.454587Complete curve; high efficacy-8.22921.41630.968736.1127176.5672-1.10 0 0 0 0 0 0 0 0 0 010.8624168.6765147.515496.349154.200241.544537.572842.209341.742240.483343.494610.8624QC'd by Cayman
Cytotoxic0.013279.744487Complete curve; high efficacy-7.87920.60.898641.6151121.3595-1.10 0 0 0 0 0 0 0 0 0 026.1462113.0499103.137682.203181.485258.693853.314553.669254.537937.118656.47926.1462QC'd by SigmaAldrich
Cytotoxic0.166378.942786Complete curve; high efficacy-6.77923.92950.945949.4968128.4395-1.10 0 0 0 0 0 0 0 0 0 039.1638119.9619118.7114121.8873145.134135.660277.501949.371642.704855.488760.915639.1638QC'd by SynKinase
Cytotoxic0.117799.522986Complete curve; high efficacy-6.92920.50.978453.5004153.0233-1.10 0 0 0 0 0 0 0 0 0 054.2364146.2425146.4285127.5196118.6607112.3725102.003786.351770.597462.725470.168354.2364QC'd by Selleck
Cytotoxic0.234879.922286Complete curve; high efficacy-6.62921.46410.979158.9416138.8638-1.10 0 0 0 0 0 0 0 0 0 062.4132143.4278135.9313129.1028144.3799129.2524105.203973.502570.461953.739757.639662.4132QC'd by BIOMOL
Cytotoxic0.0187133.261986Complete curve; high efficacy-7.72920.60.944135.7906169.0525-1.10 0 0 0 0 0 0 0 0 0 027.5582156.1894139.4018135.437491.108661.224166.094967.717153.596142.584230.965227.5582QC'd by Toronto Research
Cytotoxic0.029679.81285Complete curve; high efficacy-7.52923.1320.836730.4945110.3065-1.10 0 0 0 0 0 0 0 0 0 0-0.421991.4427118.502121.280287.417839.0630.378326.00428.811631.88664.9696-0.4219QC'd by ChemAxon
Cytotoxic0.468672.558485Complete curve; high efficacy-6.32921.47810.89858.4082130.9666-1.10 0 0 0 0 0 0 0 0 0 036.5241121.5091138.67123.1995141.6082124.8321119.084385.203570.543862.760678.203936.5241QC'd by SIGMA
Cytotoxic0.574989.317185Complete curve; high efficacy-6.24043.51170.938153.4216142.7387-1.10 0 0 0 0 0 0 0 0 0 042.1397122.2594133.5752138.8262155.9137150.9759155.3277133.833270.150756.140464.45942.1397QC'd by Selleck
Cytotoxic0.104990.112685Complete curve; high efficacy-6.97921.10.9642.4601132.5727-1.10 0 0 0 0 0 0 0 0 0 048.0597134.7202138.2028122.4795111.2704105.46677.884945.23345.497230.823755.272548.0597QC'd by Tocris
Cytotoxic0.041880.357885Complete curve; high efficacy-7.37920.60.851133.6315113.9892-1.10 0 0 0 0 0 0 0 0 0 011.0841101.2736106.771596.716682.13570.480940.105551.505451.453654.137541.943611.0841QC'd by Microsource
Cytotoxic0.661994.77385Complete curve; high efficacy-6.17921.47810.980353.7716148.5446-1.10 0 0 0 0 0 0 0 0 0 055.0629148.0214138.5482154.1536143.4321157.4598136.588499.863477.243358.434452.819555.0629QC'd by Selleck
Cytotoxic0.2093116.503485Complete curve; high efficacy-6.67921.3310.904546.5044163.0078-1.10 0 0 0 0 0 0 0 0 0 013.0869143.6239161.4686168.1578159.9801164.488797.670664.784668.491371.476350.62513.0869QC'd by Selleck
Cytotoxic0.295796.448284Complete curve; high efficacy-6.52921.82650.979336.1131132.5613-1.10 0 0 0 0 0 0 0 0 0 027.7595137.6757133.1247125.0579141.4133118.8792106.669652.975840.619540.756544.348527.7595QC'd by BIOMOL
Cytotoxic0.372296.5784Complete curve; high efficacy-6.42921.47870.980840.3311136.901-1.10 0 0 0 0 0 0 0 0 0 041.4841141.6948138.6029123.988145.2114122.9084114.816475.052646.365545.832838.682941.4841QC'd by BIOMOL
Cytotoxic0.013299.542284Complete curve; high efficacy-7.87920.50.859825.2368124.779-1.10 0 0 0 0 0 0 0 0 0 033.6254113.8403106.930467.885457.737956.717356.006446.273443.48929.15714.453233.6254QC'd by NCGCChem
Cytotoxic2.093175.060284Complete curve; high efficacy-5.67924.95490.948360.3489135.4091-1.10 0 0 0 0 0 0 0 0 0 060.7384119.1757138.3496139.0789136.1425149.2097137.4143127.2154116.932554.542266.866760.7384QC'd by ChemAxon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Staphylococcus aureus
External ID: CHEMBL1943210
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2012
Volume: 22
Issue: 1
First Page: 225
Last Page: 230
DOI: 10.1016/j.bmcl.2011.11.059

Target ChEMBL ID: CHEMBL352
ChEMBL Target Name: Staphylococcus aureus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=250ug.mL-1
MIC=0.8ug.mL-1
MIC=62.5ug.mL-1
MIC=62.5ug.mL-1
MIC>=1000ug.mL-1
MIC>=1000ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-KMS-28PE-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Inconclusive2.093152.377810Complete curve; partial efficacy; poor fit-5.67921.210.8868207.717155.33921.40 0 0 0 1 0 0 0 0 0 1147.1164.4833155.0085150.5868148.3401116.6514156.9711173.7174168.6881199.2135202.8962147.1QC'd by Microsource
Inconclusive0.005712.519610Complete curve; partial efficacy; poor fit-8.24044.95490.312131.5823119.06271.40 0 0 0 0 0 0 0 0 0 1127.1473120.0823122.1295115.8993137.6706122.1335127.163123.7971150.7316133.1825125.6113127.1473QC'd by SIGMA
Inconclusive0.00192110Complete curve; partial efficacy; poor fit-8.72921.10.8356134.2114113.21141.40 0 0 0 0 0 0 0 0 0 1119.1302117.2114127.4759130.4637129.9536131.9164134.6866133.4534131.6405137.8111137.2931119.1302QC'd by Pharmeks
Inconclusive0.066221.510Complete curve; partial efficacy; poor fit-7.17921.96730.9617136.1907114.69071.40 0 0 0 0 0 0 0 0 0 0137.9456114.6907115.3457114.9342114.9118125.4369132.2852136.9063134.4597139.5384132.1379137.9456QC'd by Sequoia
Inconclusive0.148221.099810Complete curve; partial efficacy; poor fit-6.82920.80.8442149.6919128.59211.40 0 0 0 0 0 0 0 0 0 0151.9116131.6919128.2754129.76129.967133.7039147.8377137.7359147.2819148.9579147.0679151.9116QC'd by Tocris
Inconclusive0.083330.510Complete curve; partial efficacy; poor fit-7.07920.30.9065152.817122.3171.40 0 0 0 0 0 0 0 0 0 0149.8479126.317131.9239133.2597133.1414138.2988138.8257144.3744142.6826141.1244150.4849149.8479QC'd by APAC
Inconclusive0.0032310Complete curve; partial efficacy; poor fit-8.52920.70.9042116.673193.67311.40 0 0 0 0 0 0 0 0 0 0115.023597.6731106.1567108.9656113.5207111.3295114.3155115.674116.5526117.8964119.9437115.0235QC'd by SigmaAldrich
Inconclusive0.001925.510Complete curve; partial efficacy-8.72921.55790.7725134.9997109.49971.20 0 0 0 0 0 0 0 0 0 0138.6831113.4997125.8748129.6566135.9028133.275139.8144131.171127.5454138.1274135.3784138.6831QC'd by SigmaAldrich
Inactive0-5.02920.80.4643103.7426121.954440 0 0 0 0 0 0 0 0 0 0106.6946111.4544125.2432128.5053127.1929113.4715124.3917121.815114.296116.6521111.8738106.6946QC'd by BIOMOL
Inactive04125.6815122.8795130.2888125.1136125.6652130.3074128.7078129.9384126.7494127.6785129.7132125.6815QC'd by BIOMOL
Inactive04136.2326163.4273142.6615146.3348166.6634150.6103158.3404165.0578162.7658150.3198139.9664136.2326QC'd by BIOMOL
Inactive0-7.37920.80.6066126.3684141.901940 0 0 0 0 0 0 0 0 0 0126.5818144.4019133.558143.8479137.0521128.3337135.1801122.2906134.5644123.4653125.8628126.5818QC'd by BIOMOL
Inactive0-4.92924.95490.7372120.4574134.013840 0 0 0 0 0 0 0 0 0 0120.7168134.5138134.0383138.0285138.2397129.2732130.6596135.9635130.2877134.4747123.0085120.7168QC'd by BIOMOL
Inactive0-6.87923.1320.4017111.9315106.526540 0 0 0 0 0 0 0 0 0 1105.5505105.9315109.5176101.4274110.4744106.5334110.4821115.977107.3312113.281111.1989105.5505QC'd by BIOMOL
Inactive0-4.67924.50450.6481132.5399143.83940 0 0 0 0 0 0 0 0 0 0132.7564143.839141.5609139.3268147.1235144.923140.6337146.4103146.2306145.3224141.4193132.7564QC'd by BIOMOL
Inactive0-4.57920.90.6882159.3525129.352540 0 0 0 0 0 0 0 0 0 0151.1525125.3525127.8444130.5681128.6677140.8596130.7582127.8002131.1106130.9549139.8805151.1525QC'd by BIOMOL
Inactive0-6.97920.40.9481115.525797.048340 0 0 0 0 0 0 0 0 0 0114.535699.525798.7112102.3247103.7206107.7162106.0966108.4061110.7209110.6769114.5412114.5356QC'd by BIOMOL
Inactive0-5.17922.40640.5201113.1718140.123540 0 0 0 0 0 0 0 0 0 0115.0077144.1235142.7954132.4372151.4407117.6804133.3272147.8257140.0962131.6466114.5804115.0077QC'd by BIOMOL
Inactive04129.9994131.8514126.6454132.768130.4791123.0823132.8921130.718134.7376125.1039126.4003129.9994QC'd by BIOMOL
Inactive0-5.97923.51170.87899.8725117.809540 0 0 0 0 0 0 0 0 0 0106.7355120.8095114.2948118.894116.6347119.8485116.4782116.0413102.243498.24195.0287106.7355QC'd by BIOMOL
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:muscarinic acetylcholine receptor M1 [Homo sapiens]
External ID: CHRM1_PAM_FLUO8_1536_1X%ACT PRUN
Protocol: Assay Overview:

The purpose of this assay is to identify compounds that act as positive allosteric modulators (PAMs) and increase activity of the human M1 muscarinic receptor (CHRM1; M1) in cells pre-treated with a known agonist. In this assay, CHO-K1 cells stably expressing human M1 are loaded with the Fluo-8 calcium indicator dye, followed by addition of test compounds and subsequent treatment with the activator acetylcholine at a concentration that results in 20% activation (EC20). As designed, compounds that act as CHRM1 PAMs will increase calcium mobilization, resulting in increased intracellular calcium and relative fluorescence of the indicator dye beyond that of the EC20 of acetylcholine. Compounds are tested in singlicate at a final nominal concentration of 3 micromolar.

Protocol Summary:

The CHO-hM1 cell line was routinely cultured in T-175 sq cm flasks at 37 degrees C and 95% relative humidity (RH). The growth media consisted of Ham's F-12 Nutrient Media (F-12) supplemented with 10% v/v heat-inactivated qualified fetal bovine serum, 20 mM HEPES, 50 micrograms/mL Geneticin, and 1X antibiotic mix (penicillin and streptomycin).

The day before the assay 3000 cells in 3 microliters of growth media were seeded into each well of 1536 well microtiter plates and allowed to incubate at 37 degrees C, 5% CO2, and 95 % RH for 17-24 hours. Next, 2 microliters of the fluorogenic Fluo-8 intracellular calcium indicator mixture (prepared according to the manufacturer's protocol) was added to each well. Plates were then incubated for 1 hour at 37 degrees C, 5% CO2, and 95 % RH, followed by 30 minute incubation at room temperature. Then, 15 nL of test compound in DMSO were transferred to appropriate wells. The assay was started by performing a basal read of plate fluorescence (470-495 nm excitation and 515-575 nm emission) for 5 seconds on the FLIPR Tetra (Molecular Devices) prior to all wells being treated with an EC20 concentration of acetylcholine. Then a real time fluorescence measurement was immediately performed for the remaining 140 seconds of the assay. A ratio for each well was calculated to normalize assay data, according to the following mathematical expression:

Ratio = I_Max / I_Min

Where:

I_Max represents the maximum measured fluorescence emission intensity over the 140 second read and;
I_Min represents the minimum (basal) measured fluorescence emission intensity before compound was added.

The percent activation was calculated from the median ratio as follows:

% Activation = ( ( Ratio_Test_Compound - Median_Ratio_Low_Control ) / ( Median_Ratio_High_Control - Median_Ratio_Low_Control ) ) * 100

Where:

Test_Compound is defined as wells containing test compound.
Low_Control is defined as wells containing Acetylcholine at EC20 and DMSO.
High_Control is defined as wells containing Acetylcholine (EC100) and DMSO.

A mathematical algorithm was used to determine nominally activating compounds in the primary screen. Two values were calculated for each assay plate: (1) the average percent activation of test compound wells and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter on an individual plate basis, i.e. any compound that exhibited greater % activation than the plate based cutoff parameter was declared active.

PubChem Activity Outcome and Score:

The inactive compounds of this assay have an activity score range of 0 to 78 and the active compounds have an activity score range of 50 to 100.

The reported PubChem Activity Score has been normalized to 100% observed primary activation. Negative % activation values are reported as activity score zero.

List of Reagents:

Cell line: Chinese Hamster Ovary (CHO) cells containing hM1 receptor; (Conn Lab)
Calcium sensitive dye: Fluo-8 No Wash Calcium Assay Kit; (AAT Bioquest, part 36316)
Growth media: Ham's F-12; 10% FBS, 20mM HEPES, 50?g/mL G418
Assay media: Ham's F-12, 10% FBS, 20 mM HEPES
Assay plates: Aurora black/clear 1536well FLIPR plate; (Aurora, part 00019326)
Probenecid: 250mM (pH 8.0); (Sigma P8761)
Potentiator: Acetylcholine (50mM stock in water); Sigma A9187
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, and compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Activation at 3 uM
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.74
9.74
9.74
9.74
9.74
9.74
9.74
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Staphylococcus aureus
External ID: CHEMBL1943209
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2012
Volume: 22
Issue: 1
First Page: 225
Last Page: 230
DOI: 10.1016/j.bmcl.2011.11.059

Target ChEMBL ID: CHEMBL352
ChEMBL Target Name: Staphylococcus aureus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=250ug.mL-1
MIC=0.8ug.mL-1
MIC=62.5ug.mL-1
MIC=15.62ug.mL-1
MIC>=1000ug.mL-1
MIC>=1000ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-LP_1-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.010587.390386Complete curve; high efficacy-7.97921.55790.989332.5525119.9428-1.10 0 0 0 0 0 0 0 0 0 032.5973120.122108.670192.358749.68844.854932.131433.603134.763228.3332.048332.5973QC'd by Tocris
Cytotoxic0.008376.084786Complete curve; high efficacy-8.07922.40640.978834.0695110.1542-1.10 0 0 0 0 0 0 0 0 0 024.173108.041107.758381.913639.516542.556837.70132.500733.657937.059831.016624.173QC'd by Toronto Research
Cytotoxic0.018777.542886Complete curve; high efficacy-7.72921.78850.962734.3529111.8957-1.10 0 0 0 0 0 0 0 0 0 033.0008112.3533115.065889.919978.411730.490234.730734.354633.092838.520140.803433.0008QC'd by Selleck
Cytotoxic0.05988.700585Complete curve; high efficacy-7.22920.60.969436.3948125.0953-1.10 0 0 0 0 0 0 0 0 0 028.5989117.1885119.5312102.469690.645885.862360.636451.829952.266249.734541.128528.5989QC'd by Selleck
Cytotoxic0.033277.128185Complete curve; high efficacy-7.47920.70.965531.2029108.331-1.10 0 0 0 0 0 0 0 0 0 022.5571101.2018101.265588.845670.184569.842243.682140.23739.306637.25836.404722.5571QC'd by Selleck
Cytotoxic0.018779.858785Complete curve; high efficacy-7.72923.51170.958432.0611111.9199-1.10 0 0 0 0 0 0 0 0 0 013.2093112.4294107.1384115.125260.413141.924537.316331.47637.27735.928730.843213.2093QC'd by Cayman
Cytotoxic0.093586.449185Complete curve; high efficacy-7.02921.10.944937.248123.6972-1.10 0 0 0 0 0 0 0 0 0 026.2605129.9165117.2503108.9438120.53891.515551.119756.159151.860742.057332.899826.2605QC'd by Tocris
Cytotoxic0.020993.129385Complete curve; high efficacy-7.67921.46410.961833.1188126.2481-1.10 0 0 0 0 0 0 0 0 0 022.4794117.474125.7046121.844767.966156.055641.326142.215733.927132.351729.697222.4794QC'd by Selleck
Cytotoxic0.0332100.48585Complete curve; high efficacy-7.479210.970731.2298131.7149-1.10 0 0 0 0 0 0 0 0 0 025.5067135.567116.3384110.9262105.252653.915347.874942.057435.306632.7930.969525.5067QC'd by SIGMA
Cytotoxic0.029693.442184Complete curve; high efficacy-7.52923.92950.974823.6719117.114-1.10 0 0 0 0 0 0 0 0 0 025.7428100130.2442120.83397.558327.822521.54819.831323.18926.683424.643725.7428QC'd by SigmaAldrich
Cytotoxic0.372276.55184Complete curve; high efficacy-6.42921.210.930841.5458118.0968-1.10 0 0 0 0 0 0 0 0 0 026.8735126.0105102.8329112.503124.3981120.178987.830470.201454.107949.917250.88526.8735QC'd by ChemieTek
Cytotoxic0.132181.241484Complete curve; high efficacy-6.87924.95490.942234.404115.6454-1.10 0 0 0 0 0 0 0 0 0 026.3475111.8181103.4247109.6276115.8533135.698144.775439.68148.652328.651829.112426.3475QC'd by Microsource
Cytotoxic0.148282.701584Complete curve; high efficacy-6.82923.92950.980732.7831115.4845-1.10 0 0 0 0 0 0 0 0 0 029.9601112.1327117.5155121.9023104.2805119.069555.455342.556433.026630.915628.938629.9601QC'd by Selleck
Cytotoxic0.05976.700284Complete curve; high efficacy-7.22921.50950.976329.9655106.6658-1.10 0 0 0 0 0 0 0 0 0 021.9818106.9151109.4753101.075790.329271.880834.561430.807840.756634.092828.492121.9818QC'd by SantaCruz Bio
Cytotoxic0.020988.802383Complete curve; high efficacy-7.67923.51170.951216.2799105.0822-1.10 0 0 0 0 0 0 0 0 0 03.7081100.414107.4471102.660964.97134.98339.840114.997917.73926.496734.02243.7081QC'd by SIGMA
Cytotoxic0.041893.574583Complete curve; high efficacy-7.37922.18760.998417.8156111.39-1.10 0 0 0 0 0 0 0 0 0 017.4361109.284114.2073106.670495.671445.860321.91818.883416.506916.328316.984617.4361QC'd by ACC
Cytotoxic0.083378.232883Complete curve; high efficacy-7.07920.80.905521.999100.2318-1.10 0 0 0 0 0 0 0 0 0 02.109590.1163103.264689.018286.322667.714235.347539.808535.914336.921628.83652.1095QC'd by ChemAxon
Cytotoxic0.074390.137383Complete curve; high efficacy-7.12920.60.939423.0787113.2161-1.10 0 0 0 0 0 0 0 0 0 014.6398104.4157102.1008106.636185.983463.333350.656440.15953.402331.917625.558714.6398QC'd by Axon Medchem
Cytotoxic0.041884.768783Complete curve; high efficacy-7.37921.22210.965421.7645106.5332-1.10 0 0 0 0 0 0 0 0 0 018.8147105.573699.2727109.218868.570462.902925.88328.211225.408922.860621.049818.8147QC'd by Selleck
Cytotoxic0.0469101.067483Complete curve; high efficacy-7.32920.90.956722.9637124.0311-1.10 0 0 0 0 0 0 0 0 0 07.6524111.1073130.7357106.619390.519265.038238.879739.549834.132432.242524.93497.6524QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Staphylococcus aureus
External ID: CHEMBL1943212
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2012
Volume: 22
Issue: 1
First Page: 225
Last Page: 230
DOI: 10.1016/j.bmcl.2011.11.059

Target ChEMBL ID: CHEMBL352
ChEMBL Target Name: Staphylococcus aureus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=250ug.mL-1
MIC=0.8ug.mL-1
MIC=62.5ug.mL-1
MIC=62.5ug.mL-1
MIC>=1000ug.mL-1
MIC>=1000ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-MOLP-8-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.2348112.884984Complete curve; high efficacy-6.62920.40.939237.0886149.9734-1.11 0 0 0 0 0 0 0 0 0 047.4866100.2991140.8419123.7999110.5725117.564587.825378.249885.531267.105248.08847.4866QC'd by SantaCruz Bio
Cytotoxic0.0332135.867784Complete curve; high efficacy-7.47920.40.868624.8504160.7181-1.10 0 0 0 0 0 0 0 0 0 09.5856132.6885149.7338116.748673.778973.989769.730568.018654.415855.950840.44799.5856QC'd by SIGMA
Cytotoxic2.0931100.118383Complete curve; high efficacy-5.67920.40.953450.966151.0844-1.10 0 0 0 0 0 0 0 0 0 067.4421149.8224143.8978144.1774136.6925121.0787121.338115.4935112.696598.792974.828167.4421QC'd by Tocris
Cytotoxic0.0132104.008283Complete curve; high efficacy-7.87921.92820.988715.4484119.4565-1.10 0 0 0 0 0 0 0 0 0 04.6572119.4565113.395898.070346.344719.738622.763617.901420.621915.88212.51264.6572QC'd by Selleck
Cytotoxic0.0235123.025483Complete curve; high efficacy-7.62920.40.833719.8641142.8896-1.10 0 0 0 0 0 0 0 0 0 012.2641131.0145115.543690.295153.905271.215162.338757.160461.969514.810235.382712.2641QC'd by Cayman
Cytotoxic0.209385.298783Complete curve; high efficacy-6.67920.70.933425.0186110.3173-1.10 0 0 0 0 0 0 0 0 0 027.0991109.8173117.737596.065379.189496.830975.536451.699233.826328.186136.413327.0991QC'd by NCGCChem
Cytotoxic3.317381.307483Complete curve; high efficacy-5.47922.33320.931557.6371138.9446-1.10 0 0 0 1 0 0 0 0 0 049.2543138.4338143.9848151.4142126.008995.5126125.5596148.3456124.31378.15369.765749.2543QC'd by Selleck
Cytotoxic0.005936.966482Complete curve; partial efficacy-8.22922.33320.9077119.6572156.6236-1.20 0 0 0 0 0 0 0 0 0 0121.5044156.5384152.389136.5428116.1001121.0618114.6459112.3913119.9242122.9008128.5083121.5044QC'd by Tocris
Cytotoxic0.0235114.209482Complete curve; high efficacy-7.62920.50.976314.7696128.979-1.10 0 0 0 0 0 0 0 0 0 010.4187119.189695.722479.624580.242657.691343.007536.236630.095223.109920.65110.4187QC'd by FLUKA
Cytotoxic3.722180.870382Complete curve; high efficacy-5.42924.95490.903234.983115.8532-1.10 0 0 0 0 0 0 0 0 0 031.7555109.588598.898113.8737107.8306136.1674134.0604103.0938120.4749.927837.402931.7555QC'd by Selleck
Cytotoxic0.093590.511982Complete curve; high efficacy-7.02922.40640.907611.9163102.4282-1.10 0 0 0 0 0 0 0 0 0 012.606679.81796.8282103.1563135.242367.22833.455113.67799.624510.775711.22312.6066QC'd by Selleck
Cytotoxic0.166394.761582Complete curve; high efficacy-6.77922.25260.98616.386111.1475-1.10 0 0 0 0 0 0 0 0 0 013.149108.3556124.8245103.3906106.2074102.246958.785121.215318.077319.677216.032513.149QC'd by Selleck
Cytotoxic0.5258104.154382Complete curve; high efficacy-6.279210.941418.3838122.5381-1.10 0 0 0 0 0 0 0 0 0 011.0314104.3828126.1461116.2417132.0669128.168183.354461.552952.656732.958721.753411.0314QC'd by JohnsHopkins
Cytotoxic0.1321103.787382Complete curve; high efficacy-6.87920.90.96614.4792118.2664-1.10 0 0 0 0 0 0 0 0 0 017.9536125.3305107.6763112.1488100.702673.069975.951528.288418.604519.064616.652717.9536QC'd by Axon Medchem
Cytotoxic0.0132114.512182Complete curve; high efficacy-7.87922.04790.990314.6838129.1959-1.10 0 0 0 0 0 0 0 0 0 013.3585136.7296116.4775107.708242.698923.621911.168115.726818.095413.321414.334613.3585QC'd by ChemieTek
Cytotoxic0.1321156.013482Complete curve; high efficacy-6.87920.40.9789-13.9595142.0539-1.10 0 0 0 0 0 0 0 0 0 02.982129.411119.3857103.9503100.891163.90856.490249.420432.44885.10223.55372.982QC'd by Selleck
Cytotoxic3.722184.036682Complete curve; high efficacy-5.42921.98870.889233.1062117.1428-1.10 0 0 0 0 0 0 0 0 0 022.583104.9664128.4651118.0164124.042993.0546124.0918125.7379103.197156.428452.504522.583QC'd by XcessBio
Cytotoxic1.320784.378182Complete curve; high efficacy-5.87924.44950.910828.6573113.0354-1.10 0 0 0 0 0 0 0 0 0 050.695598.1375111.271125.1555106.5195116.7283107.7109122.303149.824127.93655.97250.6955QC'd by Microsource
Cytotoxic0.525893.379882Complete curve; high efficacy-6.27922.33320.98319.1033112.4831-1.10 0 0 0 0 0 0 0 0 0 016.8591105.468124.7832114.5473109.601102.2654109.906561.363223.850621.146220.522416.8591QC'd by Selleck
Cytotoxic0.052698.055282Complete curve; high efficacy-7.27921.50950.986815.7184113.7736-1.10 0 0 0 0 0 0 0 0 0 012.9644114.8405118.277999.487995.383561.412321.163723.874615.920820.047211.588312.9644QC'd by Axon Medchem
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Staphylococcus aureus
External ID: CHEMBL1943211
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2012
Volume: 22
Issue: 1
First Page: 225
Last Page: 230
DOI: 10.1016/j.bmcl.2011.11.059

Target ChEMBL ID: CHEMBL352
ChEMBL Target Name: Staphylococcus aureus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=250ug.mL-1
MIC=0.8ug.mL-1
MIC=62.5ug.mL-1
MIC=62.5ug.mL-1
MIC>=1000ug.mL-1
MIC>=1000ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-MM-M1-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.010576.742198Complete curve; high efficacy-7.97920.40.8143106.1488182.891-1.10 0 0 0 0 0 0 0 0 0 097.0213175.2098149.2496135.4049151.407123.166130.2765116.1855114.3842112.5027122.711897.0213QC'd by SigmaAldrich
Cytotoxic0.020959.606490Complete curve; high efficacy-7.67922.33320.874365.0446124.6509-1.10 0 0 0 0 0 0 0 0 0 042.5491114.2054125.0887133.638390.399669.076975.433362.892474.984266.982668.241342.5491QC'd by Selleck
Cytotoxic0.018799.387289Complete curve; high efficacy-7.72920.70.980954.5973153.9845-1.10 0 0 0 0 0 0 0 0 0 052144.7606143.678116.218996.581992.313370.116662.478959.112861.584152.567552QC'd by SynKinase
Cytotoxic0.417668.959788Complete curve; high efficacy-6.37923.51170.895189.8298158.7896-1.11 0 0 0 0 0 0 0 0 0 095.9522121.7497145.5234145.5172164.4127183.3401150.4309108.335677.511895.882489.823695.9522QC'd by Axon Medchem
Cytotoxic0.589969.181988Complete curve; high efficacy-6.22923.990.762995.3406164.5224-1.10 0 0 0 0 0 0 0 0 0 0109.573149.3937173.4718129.8513191.2497150.3213190.3378133.864783.187296.413691.5262109.573QC'd by Selleck
Cytotoxic0.0743107.054887Complete curve; high efficacy-7.12920.80.984554.8206161.8754-1.10 0 0 0 0 0 0 0 0 0 057.9387151.8563163.9611143.7973136.7288112.919683.16276.873368.177453.226952.637857.9387QC'd by Selleck
Cytotoxic0.148283.542787Complete curve; high efficacy-6.82924.44950.95860.4745144.0173-1.10 0 0 0 0 0 0 0 0 0 069.2734130.5346130.6652147.3751155.1668153.941881.695563.29659.260855.616355.513469.2734QC'd by Selleck
Cytotoxic1.177117.97687Complete curve; high efficacy-5.92920.30.8809103.6252221.6012-1.10 0 0 0 0 0 0 0 0 0 0124.3584204.1012213.7323210.6584195.2614187.4914165.4267159.6533180.5857156.7486132.0473124.3584QC'd by Microsource
Cytotoxic0.005986.11287Complete curve; high efficacy-8.22923.92950.940835.788121.9-1.10 0 0 0 0 0 0 0 0 0 016.9728119.2292123.80460.906149.612339.010736.652141.355244.341829.622331.979616.9728QC'd by Selleck
Cytotoxic0.661977.798687Complete curve; high efficacy-6.17921.46410.905587.7533165.5518-1.11 0 0 0 0 0 0 0 0 0 081.2811136.4201144.0668155.7612179.4399178.5787159.509126.3915103.3855100.192987.184981.2811QC'd by Selleck
Cytotoxic0.132189.890486Complete curve; high efficacy-6.87920.80.95149.0129138.9033-1.10 0 0 0 0 0 0 0 0 0 040.8231126.0203148.1813124.8099131.8805103.371579.016473.44667.02155.440553.384540.8231QC'd by Toronto Research
Cytotoxic0.4176102.258786Complete curve; high efficacy-6.37920.90.955864.4239166.6826-1.10 0 0 0 0 0 0 0 0 0 062.0508169.9186163.4857169.1241146.548155.8497143.523295.509585.826689.782263.021662.0508QC'd by JohnsHopkins
Cytotoxic1.481876.048286Complete curve; high efficacy-5.82921.64360.961186.8287162.8769-1.11 0 0 0 0 0 0 0 0 0 082.8262126.6031167.7674148.1546170.4052160.7596163.2256153.9322115.8888102.739187.384382.8262QC'd by Microsource
Cytotoxic0.93570.299185Complete curve; high efficacy-6.02921.10.944964.9721135.2712-1.10 0 0 0 0 0 0 0 0 0 054.1264136.8416133.7919124.0367139.8306136.3935126.542109.431383.56279.460279.257954.1264QC'd by Selleck
Cytotoxic0.1049113.233785Complete curve; high efficacy-6.97921.10.946739.4295152.6631-1.10 0 0 0 0 0 0 0 0 0 032.5405140.1803150.363153.1014157.369294.872271.375973.052248.593136.378239.149432.5405QC'd by Selleck
Cytotoxic0.0166145.913585Complete curve; high efficacy-7.77920.70.982429.6583175.5718-1.10 0 0 0 0 0 0 0 0 0 034.6378162.9357140.528136.147383.994477.337854.505136.927832.978933.61429.924334.6378QC'd by Selleck
Cytotoxic0.742787.807885Complete curve; high efficacy-6.12921.82650.8961.3799149.1877-1.10 0 0 0 0 0 0 0 0 0 043.6517125.4482151.4934151.5693138.7177162.0934165.3929104.484285.588670.237469.183243.6517QC'd by SynKinase
Cytotoxic0.002672.145785Complete curve; high efficacy-8.57921.22210.943724.741896.8875-1.10 0 0 0 0 0 0 0 0 0 016.212489.740360.566940.694133.868835.347627.530728.413321.997521.291722.494316.2124QC'd by Selleck
Cytotoxic0.935100.642185Complete curve; high efficacy-6.02920.70.92361.7833162.4254-1.10 0 0 0 0 0 0 0 0 0 057.3523168.1282144.1115151.7026171.4086158.4019133.5552112.5955103.328285.466988.368357.3523QC'd by Selleck
Cytotoxic2.635188.832385Complete curve; high efficacy-5.57920.80.900992.8317181.664-1.10 0 0 0 0 0 0 0 0 0 098.7032172.664175.775187.4451189.4966178.714170.8024149.3555161.8016111.5356120.77798.7032QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Vero
External ID: CHEMBL1943214
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2012
Volume: 22
Issue: 1
First Page: 225
Last Page: 230
DOI: 10.1016/j.bmcl.2011.11.059

Target ChEMBL ID: CHEMBL391
ChEMBL Target Name: Vero
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard Value
Ratio CC50/IC50=5.9
Ratio CC50/IC50=14.8
Ratio CC50/IC50=23.25
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-OCI_MY1-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.093583.133787Complete curve; high efficacy-7.02920.60.973252.9139136.0477-1.10 0 0 0 0 0 0 0 0 0 054.7559135.1374118.648125.1116118.336796.366979.597475.149571.390359.692254.239654.7559QC'd by Selleck
Cytotoxic0.0332111.725186Complete curve; high efficacy-7.47920.30.926242.1257153.8508-1.10 0 0 0 0 0 0 0 0 0 051.7825144.6362112.8549103.828595.219288.923187.26580.966170.718165.599553.464751.7825QC'd by Cayman
Cytotoxic0.041882.751485Complete curve; high efficacy-7.37920.50.975933.8657116.617-1.10 0 0 0 0 0 0 0 0 0 028.5726108.62298.686993.798783.828667.416856.438356.969748.110946.342837.744328.5726QC'd by SynKinase
Cytotoxic0.029692.090785Complete curve; high efficacy-7.52920.50.938335.476127.5667-1.10 0 0 0 0 0 0 0 0 0 029.5556114.1336120.894588.726181.575576.202554.682455.648457.304545.91137.137429.5556QC'd by SynKinase
Cytotoxic0.186570.386984Complete curve; high efficacy-6.72922.72020.976138.0815108.4684-1.10 0 0 0 0 0 0 0 0 0 047.1917108.8739108.2531101.5408112.4163108.138570.335743.665234.539228.36141.664847.1917QC'd by JohnsHopkins
Cytotoxic0.417671.667384Complete curve; high efficacy-6.37922.40640.947943.4067115.074-1.10 0 0 0 0 0 0 0 0 0 033.3089105.574126.981118.3238117.612103.7019109.683463.443852.586453.630639.122233.3089QC'd by Selleck
Cytotoxic0.1049108.159184Complete curve; high efficacy-6.97920.30.95531.5875139.7466-1.10 0 0 0 0 0 0 0 0 0 043.3364131.0144114.5692101.756397.195681.028979.285179.03469.839955.06552.703143.3364QC'd by SynKinase
Cytotoxic0.0166112.88483Complete curve; high efficacy-7.77922.72020.988916.1533129.0373-1.10 0 0 0 0 0 0 0 0 0 013.2676116.3272134.3166126.014155.794523.838515.933916.952314.530314.265815.832113.2676QC'd by SIGMA
Cytotoxic0.468694.725883Complete curve; high efficacy-6.32920.60.955729.0284123.7542-1.10 0 0 0 0 0 0 0 0 0 035.6827133.5399103.9822117.9539112.0859105.55983.299274.084264.511341.029741.637235.6827QC'd by Selleck
Cytotoxic0.2635100.875583Complete curve; high efficacy-6.57920.90.896925.7615126.637-1.10 0 0 0 0 0 0 0 0 0 04.542104.9981131.3946122.3505135.6872112.0566.048557.839653.797641.533237.99754.542QC'd by ChemAxon
Cytotoxic0.0469103.265883Complete curve; high efficacy-7.32921.47870.994524.4756127.7413-1.10 0 0 0 0 0 0 0 0 0 022.0142133.8948120.7681119.4508105.615665.752534.739831.818124.476924.170924.920822.0142QC'd by Selleck
Cytotoxic0.468692.471283Complete curve; high efficacy-6.32922.33320.97228.9592121.4304-1.10 0 0 0 0 0 0 0 0 0 029.8907112.9759141.5986120.5517113.8929115.8225112.497662.870633.523828.959228.871129.8907QC'd by Selleck
Cytotoxic0.234889.204483Complete curve; high efficacy-6.62921.46410.977529.1453118.3497-1.10 0 0 0 0 0 0 0 0 0 030.577122.3185120.0124103.9641116.9025116.682575.578553.39729.776427.630331.59430.577QC'd by Selleck
Cytotoxic2.635188.363983Complete curve; high efficacy-5.579210.833353.4354141.7993-1.10 0 0 0 0 0 0 0 0 0 069.1826150.707126.8073140.1173122.6532128.5218127.1755136.3873123.344463.498261.630569.1826QC'd by Chemscene
Cytotoxic1.04994.696982Complete curve; high efficacy-5.97921.92820.986426.5166121.2135-1.10 0 0 0 0 0 0 0 0 0 022.4036111.8163115.5011118.7274126.8177125.7155124.411199.239253.489634.159726.65422.4036QC'd by BIOMOL
Cytotoxic0.132181.439182Complete curve; high efficacy-6.879210.970513.202594.6416-1.10 0 0 0 0 0 0 0 0 0 06.269984.6416100.214488.005489.829466.870145.105225.58927.265521.16810.12696.2699QC'd by Selleck
Cytotoxic0.083392.852382Complete curve; high efficacy-7.07920.40.970612.2421105.0944-1.10 0 0 0 0 0 0 0 0 0 015.231897.301484.070587.11564.466159.841648.860238.500140.277931.426921.966115.2318QC'd by Selleck
Cytotoxic0.023580.806982Complete curve; high efficacy-7.62920.60.988914.690995.4978-1.10 0 0 0 0 0 0 0 0 0 011.797688.131284.02266.582754.926541.216133.27229.074823.708316.203515.847511.7976QC'd by Tocris
Cytotoxic0.001259.123982Complete curve; partial efficacy-8.92924.95490.858799.4449158.5687-1.20 0 0 0 0 0 0 0 0 0 0103.2631152.614894.492295.000194.342694.4109100.4664111.3588107.5709103.868592.1541103.2631QC'd by Selleck
Cytotoxic0.417694.690582Complete curve; high efficacy-6.37922.18760.986124.3029118.9934-1.10 0 0 0 0 0 0 0 0 0 021.4583113.0531121.9635115.8336128.0296109.3466109.274655.291834.103826.512620.023521.4583QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Staphylococcus aureus
External ID: CHEMBL1943213
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2012
Volume: 22
Issue: 1
First Page: 225
Last Page: 230
DOI: 10.1016/j.bmcl.2011.11.059

Target ChEMBL ID: CHEMBL352
ChEMBL Target Name: Staphylococcus aureus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
MIC=250ug.mL-1
MIC=0.2ug.mL-1
MIC=31.25ug.mL-1
MIC=31.25ug.mL-1
MIC=7.8ug.mL-1
MIC=500ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-keats_NCIH929-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.148296.190585Complete curve; high efficacy-6.82923.92950.992444.5048140.6953-1.10 0 0 0 0 0 0 0 0 0 037.5464136.9515141.9942144.5132137.0086139.274769.470850.205143.474741.413450.930437.5464QC'd by JohnsHopkins
Cytotoxic0.012983.536684Complete curve; high efficacy-7.89041.47870.997823.8147107.3513-1.10 0 0 0 0 0 0 0 0 0 023.9151110.1823102.343496.995170.752740.620228.6625.881524.655321.871925.213523.9151QC'd by Chemscene
Cytotoxic0.023592.464784Complete curve; high efficacy-7.62921.96730.956723.2254115.6902-1.10 0 0 0 0 0 0 0 0 0 04.0573111.7434116.8232109.391975.447232.990933.705930.026330.264932.170612.76854.0573QC'd by ChemieTek
Cytotoxic0.288175.880584Complete curve; high efficacy-6.54041.82650.968341.6685117.5491-1.10 0 0 0 0 0 0 0 0 0 036.3204119.5479107.4971113.5971126.3084112.3175118.484679.974545.966145.122348.307136.3204QC'd by Selleck
Cytotoxic0.295781.009684Complete curve; high efficacy-6.52923.19250.926140.4734121.483-1.10 0 0 0 0 0 0 0 0 0 011.322115.4342118.2478121.3497132.2979117.0883107.092749.913546.654851.648750.637411.322QC'd by Prestwick Chemical; Inc.
Cytotoxic0.2635116.509584Complete curve; high efficacy-6.57920.60.970641.249157.7585-1.10 0 0 0 0 0 0 0 0 0 040.8193148.2389152.8144145.5181150.8832117.900795.735582.368280.769561.721251.108540.8193QC'd by Toronto Research
Cytotoxic0.052688.20883Complete curve; high efficacy-7.27921.28760.994223.4223111.6302-1.10 0 0 0 0 0 0 0 0 0 017.5003110.0308111.5061103.845494.601259.384438.839430.849224.832526.413122.221717.5003QC'd by LC Labs
Cytotoxic0.052675.902483Complete curve; high efficacy-7.27922.04790.973721.174997.0774-1.10 0 0 0 0 0 0 0 0 0 018.3476101.803486.025499.482590.080350.384429.228830.857823.374816.245614.543118.3476QC'd by Tocris
Cytotoxic0.052679.925683Complete curve; high efficacy-7.27921.37230.966323.9977103.9232-1.10 0 0 0 0 0 0 0 0 0 017.613998.4232100.1087114.286377.500461.650832.015431.605425.732323.840827.908417.6139QC'd by SynKinase
Cytotoxic0.020990.480783Complete curve; high efficacy-7.67920.90.977517.1515107.6322-1.10 0 0 0 0 0 0 0 0 0 06.471996.9766103.361585.574958.317441.067631.175422.007623.02321.414419.28116.4719QC'd by Selleck
Cytotoxic0.005393.642383Complete curve; high efficacy-8.279210.969714.5291108.1714-1.10 0 0 0 0 0 0 0 0 0 08.149699.284981.998249.133631.068631.287422.589621.209613.435211.247510.25858.1496QC'd by SynKinase
Cytotoxic0.014894.690583Complete curve; high efficacy-7.82921.17050.98217.423112.1135-1.10 0 0 0 0 0 0 0 0 0 012.0947103.9614109.053682.852955.000727.887130.356624.600918.123514.68813.793112.0947QC'd by SynKinase
Cytotoxic0.093596.642483Complete curve; high efficacy-7.02921.66040.992224.5734121.2158-1.10 0 0 0 0 0 0 0 0 0 025.6091121.7166119.6038122.5533110.023190.71841.660937.931622.388222.677922.400325.6091QC'd by Selleck
Cytotoxic0.046982.967883Complete curve; high efficacy-7.32924.95490.917922.6763105.644-1.10 0 0 0 0 0 0 0 0 0 02.6388101.9106107.1814103.9277109.288434.581138.965938.548133.351423.30352.61952.6388QC'd by NCI
Cytotoxic0.0296105.787183Complete curve; high efficacy-7.52920.50.883422.0136127.8007-1.10 0 0 0 0 0 0 0 0 0 04.7056117.0952117.3948102.779158.640855.617851.251852.864946.062539.792825.44594.7056QC'd by Selleck
Cytotoxic0.0209126.334483Complete curve; high efficacy-7.67920.80.98917.1119143.4463-1.10 0 0 0 0 0 0 0 0 0 016.0678134.7593122.167111.586876.247354.666237.345223.48931.102310.658718.953916.0678QC'd by Tocris
Cytotoxic0.0074100.270383Complete curve; high efficacy-8.12922.04790.993616.8213117.0916-1.10 0 0 0 0 0 0 0 0 0 023.4575117.6101105.197473.040125.850513.91814.847215.041116.016216.504218.359623.4575QC'd by Selleck
Cytotoxic0.0235108.888982Complete curve; high efficacy-7.62920.70.99411.7255120.6144-1.10 0 0 0 0 0 0 0 0 0 013.4791114.531297.322186.143674.13546.996429.785423.38115.47313.144913.473313.4791QC'd by BIOMOL
Cytotoxic0.0235110.59682Complete curve; high efficacy-7.62921.62660.976412.0566122.6526-1.10 0 0 0 0 0 0 0 0 0 012.2889128.4612120.246294.57586.24920.741516.111913.685812.951413.59113.568112.2889QC'd by FLUKA
Cytotoxic0.041884.248182Complete curve; high efficacy-7.37920.80.942513.632697.8807-1.10 0 0 0 0 0 0 0 0 0 06.907782.5934102.65586.90856441.11432.79328.119227.818519.73737.48046.9077QC'd by Otava
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Staphylococcus aureus
External ID: CHEMBL1057946
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem.
Year: 2009
Volume: 17
Issue: 15
First Page: 5408
Last Page: 5413
DOI: 10.1016/j.bmc.2009.06.059

Target ChEMBL ID: CHEMBL352
ChEMBL Target Name: Staphylococcus aureus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
256MIC=256000nM
1024MIC>1024000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:MDA-MB-231
External ID: CHEMBL3784401
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Nat. Prod.
Year: 2016
Volume: 79
Issue: 1
First Page: 248
Last Page: 251
DOI: 10.1021/acs.jnatprod.5b00774

Target ChEMBL ID: CHEMBL400
ChEMBL Target Name: MDA-MB-231
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
10IC50>10000nM
10IC50>10000nM
10IC50>10000nM
10IC50>10000nM
10IC50>10000nM
6.5IC50=6500nM
6.6IC50=6600nM
0.0039IC50=3.9nM
ActivityNot Active
10IC50>10000nM
10IC50>10000nM
10IC50>10000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Staphylococcus aureus
External ID: CHEMBL1057944
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem.
Year: 2009
Volume: 17
Issue: 15
First Page: 5408
Last Page: 5413
DOI: 10.1016/j.bmc.2009.06.059

Target ChEMBL ID: CHEMBL352
ChEMBL Target Name: Staphylococcus aureus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
128MIC=128000nM
1024MIC>1024000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:MCF7
External ID: CHEMBL3784400
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Nat. Prod.
Year: 2016
Volume: 79
Issue: 1
First Page: 248
Last Page: 251
DOI: 10.1021/acs.jnatprod.5b00774

Target ChEMBL ID: CHEMBL387
ChEMBL Target Name: MCF7
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
10IC50>10000nM
10IC50>10000nM
10IC50>10000nM
10IC50>10000nM
10IC50>10000nM
0.71IC50=710nM
10IC50>10000nM
0.0074IC50=7.4nM
ActivityNot Active
7IC50=7000nM
10IC50>10000nM
10IC50>10000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Enterococcus faecalis
External ID: CHEMBL1057945
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem.
Year: 2009
Volume: 17
Issue: 15
First Page: 5408
Last Page: 5413
DOI: 10.1016/j.bmc.2009.06.059

Target ChEMBL ID: CHEMBL362
ChEMBL Target Name: Enterococcus faecalis
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
256MIC=256000nM
1024MIC>1024000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: HERG01
Protocol: NCGC Assay Protocol Summary:

HERG assay (FluxORTM thallium flux assay) was initially developed by Invitrogen/Molecular Probes, and then miniaturized into 1536-well plate in a homogeneous format by NCGC. This assay measures the activity of potassium channel using thallium dye (FluxOR) flux as surrogate measurement for potassium into the cells with a FDSS-7000 kinetic plate reader (Hamamatsu Corp., Hamamatsu City, Japan). The hERG ion channel is transduced into mammalian cells (U2OS) using a baculovirus (Bacmam) construct harboring the hERG K+ ion channel. So far we screened LOPAC1280 library (Sigma), the NTP collection of 1408 compounds, and the NCGC Pharmaceutical Collection (NPC), in which many well defined HERG blockers are present. The rank order potencies of many of these compounds are similar to that of other HERG assays (membrane potential, Rb+ flux, patch clamp, etc). This quick and homogeneous assay is also found to be sensitive, specific, and robust.

Using the FluxORTM thallium flux assay, the activity of potassium channel using thallium dye (FluxOR) flux as surrogate measurement for potassium into the cells was measured in the U2OS cell line transduced with hERG K+ ion channel using a baculovirus (Bacmam) using Opti-MEM medium (Invitrogen) containing 2% fetal calf serum (FCS, HyCone) following loading buffer addition, compound treatment for around 10 minutes and finally adding stimulation buffer. The assay was performed in black clear Kalypsys 1536-well plates. In the screen, Astemizole was used as positive controls. Library compounds were measured for their ability to cause hERG channel blockage in the cell line, as reflected by a decrease in fluorescence intensity, in a concentration-dependent manner. Data were normalized to the controls for basal activity (DMSO only) and 100% inhibition (5uM Astemizole). AC50 values were determined from concentration-response data modeled with the standard Hill equation.

qHTS protocol for hERG-U2OS cellular assay

[Step] [Parameter] [Value] [Description]

1. Day 1: Replace medium in 70-80% confluent T225 flask with 2.5 mL of hERG-BacMam virus plus 12.5 mL of phosphate buffered saline (PBS) (corresponding roughly to a multiplicity of infection ratio of 100 virus particles/cell)
2. Incubation: 4 hrs @ room Temperature in Dark
3. Reagent; Remove virus; wash once with 25 ml DPBS
4. Reagent; 35 ml culture medium
5. Incubation; 37oC overnight
6. Day2: Reagent; 3 uL; 2000 U2OS cells/well
7. Time; 4 hr; 37oC incubation
8. Loading buffer; 1 uL; 0.7X;
9. Incubation: 1hr @ RT in Dark.
10. Compounds; 23 nL; 0.59 nM to 92 uM
11. Controls; 23 nL; Astemizole 1.4 nM to 92 uM
12. Time; 10min; 37oC incubation
13. Read fluorescence Intensity on FDSS for 10 Sec with 1 sec interval
14. Reagent; 1 uL; stimulation buffer
15. Read fluorescence Intensity on FDSS for 2 min with 1 sec interval
16. Detection; Fluorescence Intensity; FDSS
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0001000000 uMActivity at 0.0003000000 uMActivity at 0.0006116734 uMActivity at 0.00133 uMActivity at 0.00297 uMActivity at 0.00673 uMActivity at 0.015 uMActivity at 0.033 uMActivity at 0.075 uMActivity at 0.167 uMActivity at 0.369 uMActivity at 0.412 uMActivity at 0.836 uMActivity at 1.842 uMActivity at 2.061 uMActivity at 4.179 uMActivity at 9.216 uMActivity at 20.61 uMActivity at 46.08 uMActivity at 92.17 uMCompound QC
Inactive04.0950.5622-0.5-17.405541 0 0 0 0 0 1 0 0 0 0 0 0 04.0358-8.1088-16.5879-0.7265-5.65844.3730.1327-9.70320.36854.1527-0.141-3.5272-0.9713-9.32034.0358QC'd by NIEHS/NTP
Activator15.848952.39750Single point of activity-4.80.40.510848.9806-3.416930 0 0 0 0 1 0 0 0 0 0 1 0 1 038.06212.0116-8.9739-7.06230-7.0944-39.2396018.733825.780800-59.539411.623748.215338.0621QC'd by NIEHS
Inactive04-1.0832-10.89741.0031-11.058-11.8883.65680.91825.31740.029-1.48932.17113.0788-19.8367-2.8584-1.0832QC'd by NIEHS/NTP
Inactive042.45982.223-1.63678.778-0.11389.22693.440711.6742-2.146511.8823-1.8078-2.0833.78254.49092.4598QC'd by NIEHS
Inactive01.85790.45754.5-21.089940 0 0 0 0 0 0 0 0 0 0 0 0 012.886-15.90830.10180.3771-0.02467.9993-3.79713.097311.63728.3022-2.66639.3202-2.3421-0.285412.886QC'd by NIEHS/NTP
Inactive04.95490.5492-6.77071.540 0 0 0 0 0 0 0 0 0 1 0 0 11.3669-1.0856-0.77651.12421.70580.7901-1.98696.09015.26593.2331-7.9279-28.3694-1.3017-10.22551.3669QC'd by NIEHS/NTP
Inactive04-5.5826-4.0359-4.4476-11.3473-11.9097-1.5507-10.1535-3.36261.3234-0.4426-13.9824-5.2512-18.0387-15.3022-5.5826QC'd by NIEHS/NTP
Inhibitor39.810751.900420Partial curve; partial efficacy-4.43.990.9828-50.13811.7623-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0-49.45943.1993-0.02692.7134-1.98075.29460.2133-0.1387-0.26252.47080.17772.53720.4925-30.4729-49.4594QC'd by NIEHS/NTP
Inactive02.33320.6977-10.8456140 0 0 0 0 0 1 0 0 0 0 1 0 1-1.1266-1.46111.2528-0.03690.02955.5889-3.03576.75064.5747-1.4797-0.1821-9.6414-1.4402-9.8713-1.1266QC'd by NIEHS/NTP
Inactive0414.60080.5397-1.6708-0.4130.96947.4259-2.25855.08697.9351-2.4752-5.6365.39961.849-2.487114.6008QC'd by NIEHS/NTP
Inactive00.70.5791-8.9231440 0 0 0 0 0 1 0 0 0 0 0 0 12.80633.51535.19381.41166.33634.612.742912.44016.0481-0.14110.3707-1.47812.4968-5.76932.8063QC'd by NIEHS/NTP
Inactive04-17.8369-10.5115-2.5586-8.8158-26.0957-0.4819-9.7892-2.01490.27332.7166-17.2183-0.47591.0932-12.7028-17.8369QC'd by NIEHS/NTP
Inactive04.95490.4427-9.7222-1.541 0 1 0 0 0 0 0 0 0 0 0 0 0-13.1018-5.53920.00687.73370.45884.0455-12.3759-6.57240.92181.9145-11.3469-7.6261-8.5179-8.6226-13.1018QC'd by NIEHS/NTP
Inactive03.1320.7434-16.07841.540 0 0 0 0 0 0 0 0 0 0 0 0 13.99653.3921-1.15561.97152.01773.8894-2.6092.87572.72384.1025-3.54462.1635-3.6983-12.9823.9965QC'd by NIEHS/NTP
Inactive047.53724.3881-20.20115.5178-1.37582.0045-1.44014.9593-2.11221.3726-3.0011-3.06771.18832.18177.5372QC'd by NIEHS/NTP
Inactive0411.45250.2692-0.1403-0.3748-11.74892.8347-5.054616.89840.0513.829-3.6094-0.51978.0326-1.547611.4525QC'd by NIEHS/NTP
Inactive049.99361.71397.16916.3352-0.34329.148-5.8673-1.564112.6111.82378.2616-0.66541.73632.63199.9936QC'd by NIEHS/NTP
Inactive0410.2340.52521.3877-1.9626-0.9425.6494-0.276911.70528.3766.8657-0.149-0.19442.6788-6.419210.234QC'd by NIEHS/NTP
Activator22.387233.89380Complete curve; partial efficacy; poor fit-4.652.25260.715133.99630.10251.40 0 0 0 0 0 0 0 0 0 0 0 0 025.52240.4272-0.9219-0.128-2.10618.1765-1.5863-10.226512.16486.8628-0.3193-6.515517.608732.268925.5224QC'd by NIEHS/NTP
Inactive049.98485.58260.0396-1.5504-1.30043.2953.988212.27428.06469.11922.031.29227.4225-2.99749.9848QC'd by NIEHS/NTP
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:HaCaT
External ID: CHEMBL1057953
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem.
Year: 2009
Volume: 17
Issue: 15
First Page: 5408
Last Page: 5413
DOI: 10.1016/j.bmc.2009.06.059

Target ChEMBL ID: CHEMBL614392
ChEMBL Target Name: HaCaT
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeActivity Comment
ActivityNot Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Enterococcus faecalis
External ID: CHEMBL1057950
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem.
Year: 2009
Volume: 17
Issue: 15
First Page: 5408
Last Page: 5413
DOI: 10.1016/j.bmc.2009.06.059

Target ChEMBL ID: CHEMBL362
ChEMBL Target Name: Enterococcus faecalis
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
128MIC=128000nM
1024MIC>1024000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:HaCaT
External ID: CHEMBL1057951
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem.
Year: 2009
Volume: 17
Issue: 15
First Page: 5408
Last Page: 5413
DOI: 10.1016/j.bmc.2009.06.059

Target ChEMBL ID: CHEMBL614392
ChEMBL Target Name: HaCaT
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeActivity Comment
ActivityNot Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Escherichia coli
External ID: CHEMBL1057948
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem.
Year: 2009
Volume: 17
Issue: 15
First Page: 5408
Last Page: 5413
DOI: 10.1016/j.bmc.2009.06.059

Target ChEMBL ID: CHEMBL354
ChEMBL Target Name: Escherichia coli
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
128MIC=128000nM
1024MIC>1024000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Beta-ketoacyl-[acyl-carrier-protein] synthase III
External ID: CHEMBL1057949
Protocol: N/A
Comment: Journal: Bioorg Med Chem
Year: 2009
Volume: 17
Issue: 15
First Page: 5408
Last Page: 5413
DOI: 10.1016/j.bmc.2009.06.059

Target ChEMBL ID: CHEMBL1795135
ChEMBL Target Name: 3-oxoacyl-[acyl-carrier-protein] synthase 3
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard RelationStandard ValueStandard Units
K=2.3810'7/M
K=1.3210'4/M
K=6.2210'6/M
K=1.1810'4/M
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: SMAD3201
Protocol: Suspensions of trypsinized HEPG2 CAGA-GFP cells were dispensed into white, tissue culture-treated, solid 1536-well plates at 5uL/well (1000 cells/well final concentration) in DMEM medium supplemented with 1% FBS. Plates were incubated at 37 degrees C for 2 hours, after which 23 nL of compounds or DMSO were delivered to each well using a pin tool. One uL of recombinant TGF-beta in DMEM (1% FBS) was then dispensed (500 pg/mL final concentration), and plates were incubated at 37 degrees C for 18 hours. Two uL of CellTiter Glo (Promega), a luminescence-based viability reagent, was dispensed, followed by a 10 minute room temperature incubation. The plates were then measured on a PerkinElmer ViewLux plate reader for luminescence (clear filter) using a 5 second exposure. The %Activity was determined from the corrected luminescence values. Wells containing media only (no cells) were used to normalize %Activity of identified toxic compounds; media-only wells corresponded to 100%Activity (complete cell-killing), while DMSO-dosed cell controls were used to normalize 0%Activity (no toxicity).

Concentration-response curves were fitted to the signals arising from the resulting luminescence. The concentration-effect curves were then classified based on curve quality (r2), response magnitude and degree of measured activity, and compounds were subsequently categorized based on their curve class. Toxic compounds showed concentration-dependent decreases in luminescence, concordant with a decrease in intracellular ATP concentration (CellTiter Glo's marker of viability), and thus a decrease in the number of viable cells. Inactive (non-toxic) compounds showed no effect on luminescence signal. Active (toxic) compounds showed concentration dependent decrease in luminescence.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description".

2. For all inactive (non-toxic) compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active (toxic) compounds, a score range was given for each curve class type given above. Active (toxic) compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.018 uMActivity at 0.037 uMActivity at 0.074 uMActivity at 0.164 uMActivity at 0.369 uMActivity at 0.461 uMActivity at 0.737 uMActivity at 0.922 uMActivity at 1.840 uMActivity at 2.300 uMActivity at 3.690 uMActivity at 4.610 uMActivity at 9.233 uMActivity at 20.57 uMActivity at 46.10 uMActivity at 92.20 uMCompound QC
Inactive40 0 0 0 00.259610.7694.1255-1.6909-0.74870.2596QC'd by "Chem Div"
Inactive40 0 0 0 0-0.8876-5.2018-3.67070.33032.9155-0.8876QC'd by "Chem Div"
Inactive40 0 0 0 0-4.2306-10.0984-0.7957-0.93222.0609-4.2306QC'd by "Chem Div"
Inactive45.8218-1.6618-3.05539.7773-4.1735.8218QC'd by "Chem Div"
Inactive4-3.265111.605-17.88485.978514.3087-3.2651QC'd by "Chem Div"
Inactive40 0 0 0 0-7.2413.20083.9728-4.51213.9811-7.241QC'd by "Chem Div"
Inactive40 0 0 0 0-9.8078.98690.34840.37287.0197-9.807QC'd by "Chem Div"
Cytotoxic17.782835.5846Partial curve; partial efficacy-4.752.30310.9974-42.6167-7.0321-2.20 0 0 0 0-39.1036-6.2767-6.4175-8.2439-13.6777-39.1036QC'd by "Chem Div"
Cytotoxic3.548140.0619Single point of activity-5.454.95490.8999-40.3659-0.3039-30 0 0 0 12.6367-8.3337.8061-1.7484-40.23322.6367QC'd by "Chem Div"
Inactive40 0 0 0 10.54241.65919.664714.274915.58960.5424QC'd by "Chem Div"
Inactive40 0 0 0 05.9628-8.298-2.31046.1361-3.44285.9628QC'd by "Chem Div"
Inactive40 0 0 0 0-1.0151-4.6247-5.8885-4.492-0.7127-1.0151QC'd by "Chem Div"
Inactive4-0.9022-1.288913.9053-1.0794.3101-0.9022QC'd by "Chem Div"
Inactive40 0 0 0 0-23.5202-1.57517.1469-12.67219.6037-23.5202QC'd by "Chem Div"
Inactive40 0 0 0 1-0.075-0.6173-0.87325.1352.1913-0.075QC'd by "Chem Div"
Cytotoxic35.481333.3813Single point of activity-4.454.95490.4913-37.3813-4-30 0 0 0 0-30.3178-0.6381-23.6633-3.83866.0591-30.3178QC'd by "Chem Div"
Inactive40 0 0 0 0-17.4140.1464-4.8771-5.0687-7.6162-17.414QC'd by "Chem Div"
Inactive4-4.6673-7.1501-3.3264-4.1232-3.249-4.6673QC'd by "Chem Div"
Inactive40 0 0 0 0-17.38786.57262.9374-7.8375-3.1433-17.3878QC'd by "Chem Div"
Inactive40 0 0 0 1-10.2269-7.0609-5.5812-5.82172.0518-10.2269QC'd by "Chem Div"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Burnham Center for Chemical Genomics 靶标:cystic fibrosis transmembrane conductance regulator [Homo sapiens]
External ID: SBCCG-A764-CF-PAF-Primary-Assay
Protocol: Assay Materials:
KKLEB-NFkB-GFP cells (Assay Provider)
PAF(Assay Provider)
Fetal Bovine Serum (Hyclone SH30396.03)
Penicillin Streptomycin solution
L-glutamine (100X)
TrypLE (Invitrogen 12563)
DPBS without calcium and magnesium (1X)
Corning culture flasks
Black CellBind 1536-well plates (Corning 3833)
ATPlite (Perkin Elmer 6016739)

I. Cell Suspension
1- Dispense 3 uL/well of cells at 5X10;5 cells/mL to the whole plate (plate cells in 2% FBS assay media).
2- Spin down plates on Eppendorf centrifuge 5810 at 500 rpm for 1 minute.

II. Compound Addition:
3- Transfer test compounds to columns 5-48 and DMSO to columns 1-4 using the Labcyte ECHO 555.
4- Transfer volume of test compound and DMSO is 15nL, making 5uM compound concentration at 0.25% DMSO final.
5-Spin down plates on Vspin at 1000 rpm for 1 minute.
6-Put Kalypsys metal lids on plates, incubate plates at 37 degrees C with 5% CO2 for 2 hours.

III. Reagent Addition
7- Dispense 3 uL/well of serum free assay media to columns 1 and 2.
8- Dispense 3 uL/well of PAF (dilute in serum free assay media) to columns 3-48.
9- Spin down plates without lids on Vspin at 2000 rpm for 2 min
10- Put Kalypsys metal lids on plates, and incubate plates at 37 degrees C with 5% CO2 overnight.

IV. Reading plates:

11-Spin plates upside down with a container at 1000 rpm for 15 sec. Dab them with a tissue to dry them and Read immediately on envision for GFP fluorescence.
12-Dispense 6 uL/well of ATPlite (diluted in DPBS 1:1).
13-Spin down plates on Eppendorf centrifuge 5810 at 2000 rpm for 2 minutes without lids.
14-Incubate plates for 10 min at RT and run Luminescence read on Viewlux.
Comment: Compounds that demonstrated a corrected %Activity of >= 50% at 5 uM concentration are defined as actives in this assay.

The experimental values were normalized by the difference between values from neutral and stimulator control wells in each plate. Then normalized data was corrected to remove systematic plate patterns due to artifacts such as dispensing tip issues etc. Further information about data correction is available at http://www.genedata.com/products/screener.html.

To simplify the distinction between the inactives of the primary screen and of the confirmatory screening stage, the Tiered Activity Scoring System was developed and implemented. Its utilization for the assay is described below.

Activity Scoring
Activity scoring rules were devised to take into consideration compound efficacy, its potential interference with the assay and the screening stage that the data was obtained. Details of the Scoring System will be published elsewhere. Briefly, the outline of the scoring system utilized for the assay is as follows:
1) First tier (0-40 range) is reserved for primary and single-concentration confirmation screening data.
a. If outcome of the primary screen is inactive, then the assigned score is 0
b. If outcome of the primary screen is inconclusive, then the assigned score is 10
c. If outcome of the primary screen is active, then the assigned score is 20
d. If outcome of the single-concentration confirmation screen is inactive, then the assigned score is 21
e. If outcome of the single-concentration confirmation screen is inconclusive, then the assigned score is 25
f. If outcome of the single-concentration confirmation screen is active, then the assigned score is 30.
This scoring system helps track the stage of the testing of a particular SID. For the primary hits which are available for confirmation, their scores will be greater than 20. For those which are not further confirmed, their score will stay under 21.

2) Second tier (41-80 range) is reserved for dose-response confirmation data and is not applicable in this assay

3) Third tier (81-100 range) is reserved for resynthesized true positives and their analogues and is not applicable in this assay
%Activity at 5 uMValueMean LowStd Deviation LowMean High Std Deviation High
17.71388986164067.888625.22080144.63200104.91
-5.52023753164067.888625.22080144.63200104.91
-1.91947331164067.888625.22080144.63200104.91
4.91776516164067.888625.22080144.63200104.91
4.41681435164067.888625.22080144.63200104.91
7.11654104164067.888625.22080144.63200104.91
-16.92220014164067.888625.22080144.63200104.91
5.51825441164067.888625.22080144.63200104.91
-10.22135725164067.888625.22080144.63200104.91
13.11722580164067.888625.22080144.63200104.91
0.11996001164067.888625.22080144.63200104.91
-1.51994666164067.888625.22080144.63200104.91
12.61687553164067.888625.22080144.63200104.91
-12.42138337164067.888625.22080144.63200104.91
1.91864558164067.888625.22080144.63200104.91
14.31574274164067.888625.22080144.63200104.91
20.41414289164067.888625.22080144.63200104.91
67.4531762164067.888625.22080144.63200104.91
3.11778225164067.888625.22080144.63200104.91
53.5823431164067.888625.22080144.63200104.91
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:muscarinic acetylcholine receptor M1 [Homo sapiens]
External ID: CHRM1_ANT_FLUO8_1536_1X%INH PRUN
Protocol: Assay Overview:

The purpose of this assay is to identify compounds that act as antagonists and decrease activity of the human M1 muscarinic receptor (CHRM1; M1) that have been pre-treated with a known agonist, with the end result being a decrease in intracellular calcium. In this assay, CHO-K1 cells stably expressing human M1 are loaded with the Fluo-8 calcium indicator dye. Compounds are added followed by treatment with the activator acetylcholine at a concentration that results in 80% activation (Ec80). As designed, compounds that act as CHRM1 antagonists will decrease calcium mobilization, resulting in decreased relative fluorescence of the indicator dye below that of the Ec80 of acetylcholine. Compounds are tested in singlicate at a final nominal concentration of 3 uM.

Protocol Summary:

The CHO-hM1 cell line was routinely cultured in T-175 sq cm flasks at 37 C and 95% relative humidity (RH). The growth media consisted of Ham's F-12 Nutrient Media (F-12) supplemented with 10% v/v heat-inactivated qualified fetal bovine serum, 20 mM HEPES, 50 ug/mL Geneticin, and 1X antibiotic mix (penicillin and streptomycin).

The day before the assay 3000 cells in 3 uL of growth media were seeded into each well of 1536 well microtiter plates and allowed to incubate at 37 C, 5% CO2, and 95 % RH for 17-24 hours. Next, 2 uL of the fluorogenic Fluo-8 intracellular calcium indicator mixture (prepared according to the manufacturer's protocol) was added to each well. Plates were then incubated for 1 hour at 37 C, 5% CO2, and 95 % RH, followed by 30 minute incubation at room temperature. Then, 15 nL of test compound in DMSO were transferred to appropriate wells. The assay was started by performing a basal read of plate fluorescence (470 - 495 nm excitation and 515 - 575 nm emission) for 5 seconds on the FLIPR Tetra (Molecular Devices) prior to all wells being treated with an EC80 concentration of acetylcholine. Then a real time fluorescence measurement was immediately performed for the remaining 140 seconds of the assay.

Hits for this assay were determined according to the following mathematical expression:

Ratio = I_Max / I_Min

Where:

I_Max represents the maximum measured fluorescence emission intensity over the 140 second read and,
I_Min represents the minimum (basal) measured fluorescence emission intensity before compound was added.

The percent inhibition was calculated from the median ratio as follows:

%_Inhibition = ( 1 - ( Ratio Test_Compound - Median_Ratio_High_Control ) / ( Median_Ratio_Low_Control - Median_Ratio_High_Control ) ) ) * 100

Where:

Test_Compound is defined as wells containing test compound.
Low_Control is defined as wells containing Ec80 of acetylcholine and DMSO.
High_Control is defined as wells containing DMSO.

PubChem Activity Outcome and Score:

A mathematical algorithm was used to determine nominally inhibiting compounds in the primary screen. Two values were calculated for each assay plate: (1) the average percent inhibition of test compound wells and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter for each plate, i.e. any compound that exhibited greater % inhibition than that particular plate's cutoff parameter was declared active.

The reported PubChem Activity Score has been normalized to 100% observed inhibition. Negative % inhibition values are reported as activity score zero.

The PubChem Activity Score range for active compounds is 100-7, and for inactive compounds 80-0.

In this assay not all plates were run in the same batch. This resulted in batch-to-batch variation among the different batches of plates, thereby necessitating the use of a plate-based activity cutoff. For this reason the inactive and active scores overlap.

List of Reagents:

Cell line: Chinese Hamster Ovary (CHO) cells containing hM1 receptor; (Conn Lab)
Calcium sensitive dye: Fluo-8 No Wash Calcium Assay Kit; (AAT Bioquest, part 36316)
Growth media: Ham's F-12; 10% FBS, 20mM HEPES, 50 ug/mL G418
Assay media: Ham's F-12, 10% FBS, 20 mM HEPES
Assay plates: Aurora black/clear 1536well FLIPR plate; (Aurora, part 00019326)
Probenecid: 250mM (pH 8.0); (Sigma P8761)
Potentiator: Acetylcholine (50 mM stock in water); Sigma A9187
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, and compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Inhibition at 3 uM
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.47
6.47
6.47
6.47
6.47
6.47
6.47
6.47
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:Smad3 [Homo sapiens]
External ID: SMAD3101
Protocol: Suspensions of trypsinized HEPG2 CAGA-GFP cells were dispensed into white, tissue culture-treated, solid 1536-well plates at 5uL/well (1000 cells/well final concentration) in DMEM medium supplemented with 1% FBS. Plates were incubated at 37 degrees C for 2 hours, after which 23 nL of compounds or DMSO were delivered to each well using a pin tool. One uL of recombinant TGF-beta in DMEM (1% FBS) was then dispensed (500 pg/mL final concentration), and plates were incubated at 37 degrees C for 18 hours. The plates were measured on an Acumen eX3 Explorer plate reader for GFP fluorescence (ex488/em500-530). GFP values were calculated by determining the mean GFP fluorescence of individual cells, and compiling these values for each well to determine a total well GFP signal. The %Activity was determined from the corrected fluorescence values. A titration of the known TGF-B inhibitor SB431542 was included to monitor plate performance, while unstimulated HEPG2 (-TGF-B) control wells were used to normalize %Activity of identified inhibitors; unstimulated wells corresponded to 100%Activity (full inhibition), while stimulated cell controls (+DMSO) were used to normalize 0%Activity (no inhibition).

Concentration-response curves were fitted to the signals arising from the resulting fluorescence. The concentration-effect curves were then classified based on curve quality (r2), response magnitude and degree of measured activity, and compounds were subsequently categorized based on their curve class. Active inhibitors showed concentration-dependent decreases in GFP fluorescence, concordant with a decrease in TGF-B/SMAD3-driven GFP expression. Inactive compounds showed no effect on fluorescence signal.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.018 uMActivity at 0.037 uMActivity at 0.074 uMActivity at 0.164 uMActivity at 0.369 uMActivity at 0.461 uMActivity at 0.737 uMActivity at 0.922 uMActivity at 1.840 uMActivity at 2.300 uMActivity at 3.690 uMActivity at 4.610 uMActivity at 9.231 uMActivity at 20.57 uMActivity at 46.10 uMActivity at 92.20 uMCompound QC
Inactive40 0 0 0 027.05699.939810.15150.16715.572127.0569QC'd by "Asinex Ltd."
Inactive40 0 0 0 1-4.9362-9.41412.0824-11.0493-7.696-4.9362QC'd by "Asinex Ltd."
Inactive40 0 0 0 15.95954.342-1.5624-2.6449-8.95385.9595QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-19.7473-1.4487.5701-38.1554-17.3097-19.7473QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-1.2351-5.5487-5.0573-16.62112.7653-1.2351QC'd by "Asinex Ltd."
Inactive40 0 0 0 07.1959-7.76824.48993.399213.37077.1959QC'd by "Asinex Ltd."
Inactive40 0 0 0 18.983315.3354.25354.1946-14.32368.9833QC'd by "Asinex Ltd."
Inactive40 0 0 0 07.9022-10.517413.4936-10.46867.23237.9022QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-11.834712.2839-2.7256-19.2666-5.8034-11.8347QC'd by "Asinex Ltd."
Inhibitor35.4813106.2444Single point of activity-4.454.44950.9934-109.7251-3.4808-30 0 0 0 0-84.6645-7.4849-2.0755-4.81140.1432-84.6645QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-3.6-2.07174.941415.4055-0.2463-3.6QC'd by "Asinex Ltd."
Inactive40 0 0 0 00.7641028.345612.16980.90780.7641QC'd by "Asinex Ltd."
Inactive40 0 0 0 1-3.7338-9.95590.39868.925512.5033-3.7338QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-1.77973.8831.182-4.1851.7497-1.7797QC'd by "Asinex Ltd."
Inhibitor15.848938.9608Single point of activity-4.83.67720.9889-35.46083.5-30 0 0 0 0-32.8842.06775.8192.7318-1.3119-32.884QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-3.7978.4821-2.183612.765.4907-3.797QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-18.74991.02723.81520.51991.7606-18.7499QC'd by "Asinex Ltd."
Inactive40 0 0 0 00.46409.4101-6.52060.90670.464QC'd by "Asinex Ltd."
Inactive40 0 0 0 00.23719.7122-4.6112-6.6419-3.28890.2371QC'd by "Asinex Ltd."
Inactive40 0 0 0 13.67994.89241.7621-1.6686-4.49453.6799QC'd by "Asinex Ltd."